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 The widespread use of genomic information to improve clinical care has long been 
a goal of clinicians, researchers, and policy-makers. With the completion of the Human 
Genome Project over a decade ago, the feasibility of attaining this goal on a widespread 
basis is becoming a greater reality. In fact, new genome sequencing technologies are 
bringing the cost of obtaining a patient’s genomic information within reach of the general 
population. While this is an exciting prospect to health care, many barriers still remain to 
effectively use genomic information in a clinically meaningful way. These barriers, if not 
overcome, will limit the ability of genomic information to provide a significant impact on 
health care. Nevertheless, clinical decision support (CDS), which entails the provision of 
patient-specific knowledge to clinicians at appropriate times to enhance health care, offers 
a feasible solution. As such, this body of work represents an effort to develop a functional 
CDS solution capable of leveraging whole genome sequence information on a widespread 
basis. Many considerations were made in the design of the CDS solution in order to 
overcome the complexities of genomic information while aligning with common health 
information technology approaches and standards. This work represents an important 
advancement in the capabilities of integrating actionable genomic information within the 
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Genetics in medicine began in the early 20th century with physicians observing 
certain metabolic disorders re-occurring in families that could be explained by Mendel’s 
laws of inheritance. Over the next century, as the scientific understanding of genetics grew, 
its application in medicine has seen slow but steady growth, mostly in rare, single-gene 
disorders. However, with the recent rapid advances in genetics research and technology, 
fueled by the Human Genome Project, our understanding of genetics to human disease is 
rapidly becoming more ubiquitous across the specialties of medicine. Indeed, Dr. Francis 
Collins, the current Director of the National Institutes of Health, has stated that “virtually 
every disease has some genetic component.” 
Understanding the genetic contribution to disease etiology and individualized drug 
therapy has given rise to the field of personalized medicine, which is defined as the tailoring 
of medical treatment to the individual characteristics of each patient. The ability to 
personalize care to the individual patient is an exciting prospect to many in health care, as 
it has the potential to reduce costs and improve the quality of care. Personalized care is the 
provision of health based upon the individual characteristics, including genotype, of the 
patient. Characteristics used to provide personalized health care can include personal health 
history, genotype, biomarkers, environmental and social influences, and other attributes 
that can be used to classify or subtype an individual for personalized care. For this 
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dissertation, the primary focus is on the application of an individual’s genomic information 
to provide personalized health care. 
Given the potential of genomic information to enable personalized health care, its 
ability to be effectively leveraged in a clinical setting is important. However, many 
challenges exist which inhibit such effective clinical application of genomic information. 
These challenges will be highlighted throughout subsequent chapters. Nevertheless, we 
believe that clinical decision support (CDS) is an effective mechanism to overcome these 
challenges and support the provision of genomic information to support personalized 
medicine. CDS entails providing clinicians, patients, and other healthcare stakeholders 
with pertinent knowledge and person-specific information, intelligently filtered or 
presented at appropriate times, to enhance health and healthcare. 
Our first step in this research was to identify the body of work related to CDS for 
genetically-guided personalized medicine. For this particular effort we conducted a 
systematic review of the published literature on the topic to identify and learn from trends 
and patters. The work resulted in a Journal of the American Medical Informatics 
Association (JAMIA) publication entitled “Clinical decision support for genetically guided 
personalized medicine: a systematic review” and is found in Chapter 1 of this dissertation. 
A key finding from this research is that we identified zero publications on CDS capabilities 
for whole genome sequence (WGS) information. As a result, this set us on the course of 
researching and developing CDS capabilities for WGS information. 
To build the case of the need for CDS capabilities for WGS information, we 
authored a publication entitled “The need for clinical decision support integrated with the 
electronic health record for the clinical application of whole genome sequencing 
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information” which was published in the Journal of Personalized Medicine. This work, 
found in Chapter 2 of this dissertation, describes in detail the barriers of effectively using 
WGS information in a clinical setting. This work further describes how CDS can support 
WGS information in an effective way and illustrates several clinical scenarios in which this 
type of CDS could be leveraged.  
Subsequently, during the design process of a CDS architecture for WGS 
information, we identified several important requirements for such an architecture to be 
effective which were not identified in previous research. As a result, we developed these 
requirements into a formal desiderata and validated them among domain experts in 
genomics and CDS. This work entitled “Technical desiderata for the integration of genomic 
data with clinical decision support” is currently under review for publication. This work is 
represented in Chapter 3 of this dissertation.  
Following the development and validation of this desiderata, we designed an 
architecture approach that could satisfy the requirements of the desiderata. Indeed, this 
approach leveraged service-oriented architecture (SOA) design principles separate out 
business concerns to independently manage and control components or services. This 
approach allowed the architecture the scalability and flexibility to adapt to the challenges 
in providing WGS information to support the provision of personalized health care. This 
architecture design along with design justifications are describe in the manuscript entitled 
“A proposed clinical decision support architecture capable of supporting whole genome 
sequence information” in the Journal of Personalized Medicine and makes up Chapter 4 
of this dissertation.  
Finally, to prove that this architectural approach is a feasible solution, we developed 
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and tested a prototype patterned after the proposed architecture described above. In this 
effort, we were able to successfully develop this prototype using open source solutions and 
health information technology standards. While some of these components used required 
significant configuration or development, this effort demonstrates it is possible to use this 
approach to provide WGS-guided CDS at the point of care within the clinical workflow. 
This work is currently under review for publication and is described in Chapter 5.         
In summary, this work represents an advance in informatics solutions and 
approaches that can support genome-guided personalized medicine through CDS 
capabilities. While it may be several years before this approach can be used on a 
widespread basis and impact the general population, it provides a foundation upon which 
further research and development can be based. In fact, many opportunities exist for 
ongoing work supported by grant funding opportunities and for further journal publications 
in this area. Nevertheless, the ultimate goal is for these CDS solutions to be implemented 
in the clinical setting so that they can improve patient outcomes through personalized 
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TECHNICAL DESIDERATA FOR THE INTEGRATION 




Rapid genomic sequencing, including whole genome sequencing (WGS) and 
exome sequencing, is the future paradigm of clinical genetic testing [1]. With a patient’s 
entire genome readily available to a clinician at the point of care, WGS may offer many 
benefits to traditional single gene testing. Currently, the effective use of single gene testing 
is inhibited by several factors including the need for clinical indication prior to ordering, 
the time delay between test ordering and the return of results, and financial constraints for 
single gene tests [2]. WGS will likely overcome many such barriers in the future. For 
instance, with WGS information readily available, pathogenic variants in disease-causing 
genes can be made known to the clinician much earlier in the decision-making process to 
aid in differential diagnosis [3]. Likewise, important but clinically under-utilized use cases 
such as pharmacogenomics may now become more clinically and financially feasible than 
                                                          
1 A revised version of this chapter has been submitted to the Journal of Biomedical Informatics as a 
commentary. Co-authors of this submitted manuscript include Dr. Karen Eilbeck, Dr. Laurence Meyer, Dr. 
Guilherme Del Fiol, and Dr. Kensaku Kawamoto.  
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under the current genetic testing paradigm [4]. Indeed, the cost and value of WGS is now 
at a point at which health care providers are sequencing a patient’s genome for unique 
clinical scenarios [5,6]. As a result, it may be soon when WGS becomes a larger part of 
routine clinical care [1]. 
 
Challenge of genome data in the clinical setting 
While WGS offers many opportunities to enhance clinical care, were it to be made 
widely available for routine clinical care today, the effective use of WGS information 
would be hindered by significant barriers. These barriers include inadequate laboratory 
reporting methods, the complexity of genetic analysis, lack of physician proficiency in 
genetic analysis, and the insufficient number of genetics professionals in the workforce 
[7,8]. As clinicians are already burdened with significant time constraints, adding an 
additional layer  of WGS information that they are required to review, integrate with other 
clinical parameters, and translate into appropriate clinical actions is unlikely to be 
successful without assistance [9]. This challenge is amplified by the rapidly evolving nature 
of our understanding of the genome and its clinical implications [10]. 
 
Potential of clinical decision support 
Clinical decision support (CDS) integrated into the clinician’s workflow provides 
a practical solution to allow clinicians to provide effective clinical care using genomic 
information [11,12]. CDS entails providing clinicians, patients, and other healthcare 
stakeholders with pertinent knowledge and person-specific information, intelligently 
filtered or presented at appropriate times, to enhance health and healthcare [13]. Examples 
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of point-of-care CDS include medication dosing support, order facilitators, alerts and 
reminders, relevant information display, expert systems, and workflow support [14]. CDS 
knowledge, which supports these types of CDS, is used to process clinical data to provide 
patient-specific advice, recommendations, or information. Figure 3.1 provides summary of 
CDS types and potential examples of WGS-enabled CDS. 
When developed and implemented properly, CDS has the ability to process large 
amounts of complex data, such as WGS data, and present actionable, evidence-based 
recommendations to clinicians at the point of care [15]. In doing so, CDS has been shown 
to be effective in reducing errors, improving clinician performance, and ultimately 
improving the quality of care in clinical settings [16]. Furthermore, CDS is able to translate 
research discoveries into clinical care much more efficiently than other traditional methods 
of knowledge translation [17]. Indeed, CDS may be essential to meeting the demands of 
WGS at the point of care [18]. 
 
Masys et al. desiderata for integration of  
genomic information with EHRs 
To provide guidance on how to integrate genomic information within the EHR, 
Masys et al. [19] developed a set of guiding principles for the technical integration of 
genomic information into the electronic health record (EHR). Their summarized desiderata 
is outlined in Figure 3.2. While this paper provides a strong foundation for integration of 
genomic information within the EHR, in our experience developing CDS capabilities for 
WGS, we found that it did not fully address all the needs of WGS integration with CDS.  
To address this need, we assembled a core group of domain experts in genomics 
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and CDS to define additional desirable functional characteristics for CDS capable of 
incorporating WGS at the point of care within an EHR. These additional requirements were 
then validated and assessed for importance among a larger group of domain experts in 
genomics and CDS. This effort is intended to augment the original Masys et al. desiderata 
and provide further guidance to system developers on important requirements to consider 
when developing health IT systems and CDS for WGS information. Of note, the 
requirements described in this desiderata represent current and potential needs according 
to our current understanding. Nevertheless, future research and development may require 
additional requirements to be added or compel current requirements to be removed from 
the desiderata. As such, this initial set of requirements should be viewed as an evolving set 




Development of additional desiderata 
A core group of domain experts in genomics and CDS was assembled to review 
needs for WGS CDS. This group of domain experts derived a set of additional desiderata 
by consensus. The members of the core group consisted of the authors of this manuscript. 
Their credentials are described in Appendix A. The core group iteratively refined the 
proposed requirements with multiple rounds of revisions until an agreed upon initial set of 





Input from community domain experts 
We sought to improve, refine, and validate our initial set of requirements by seeking 
additional input and qualitative feedback from a wider community of domain experts in 
genomics and CDS. To obtain this feedback, an anonymous, internal review board (IRB) 
approved survey was distributed electronically to e-mail discussion lists of relevant expert 
groups. Participants included members of the HL7 Clinical Genomics Workgroup, HL7 
CDS Workgroup, AMIA Genomics Workgroup, AMIA CDS Workgroup, Open Source 
Electronic Health Record Agent (OSEHRA) Genomics Workgroup, the developers of 
ClinVar, University of Utah Program in Personalized Health Care, and our own 




The survey data were collected and managed using the REDCap electronic data 
capture tool hosted at the University of Utah [20]. The survey consisted of a brief 
background followed by a demographic question assessing the type of expertise the survey 
participant held (genomics, CDS, or both). Each requirement was listed and summarized 
on a separate page with a 5-point Likert scale assessing the participant’s opinion regarding 
the importance of each requirement (very important, important, neither important nor 
unimportant, unimportant, very unimportant, and unsure/no opinion/blank). Additionally, 
each requirement had a field to allow the participant to provide a comment. The survey 
concluded with a solicitation for general comments and the option for study participants to 
provide their email to be contacted again, if desired. The full survey is available in 
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Appendix B. For a participant’s response to be included in the final analysis, the study 
participant had to consent to the survey and complete greater than 50% of the Likert-scale 
questions. 
Data analysis and presentation 
Survey responses were analyzed and visualized using spreadsheet software. To 
assess significance, Likert responses for each requirement were grouped into important 
(very important and important) and nonimportant (neither important nor unimportant, 
unimportant, very unimportant). Likert scale responses for each requirement are presented 
as graphs in this manuscript (see Figure 3.1).  We used a chi square test with expected 
values based on an even selection of all values. Qualitative feedback was reviewed by the 
core panel, and feedback was incorporated into the desiderata where appropriate. 
Participant feedback, resulting modifications, and core group responses are available at 
http://tinyurl.com/nxjxr8v.     
 
Results 
A total of 108 surveys were started, of which 45 (42%) were excluded because less 
than 50% of Likert responses were completed. A total of 63 (58%) responses were included 
in the analysis; in these cases, almost all Likert questions were fully completed. Of the 
included participants, 27% were experts in genomics only, 49% were experts in CDS only, 
and 24% were experts in both CDS and genomics. The majority of included surveys (79%) 
were completed within the first week of the survey. All proposed requirements were judged 
to be important (which includes important and very important) by the community of 
experts. All results were found to be highly significant (p<10-9). The final desiderata is 
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summarized in Figure 3.3, listed in order of importance as assessed by the community of 
experts. The original order of requirements presented in the survey to study participants 
are available in Appendix B. As this is an effort to expand, not replace, the original Masys 
et al. requirements, the desiderata numbering will continue with the number eight and 
follow the same summary and description format for each requirement. Tables 
summarizing in graphical format the participant responses for each requirement are 
available at http://tinyurl.com/nxjxr8v.  
 
CDS knowledge must have the potential to incorporate multiple 
genes and clinical information (Requirement #8) 
A relatively small number of Mendelian diseases, such as cystic fibrosis and sickle-
cell anemia, are affected by variants within a single gene responsible for producing the 
characteristic phenotype. As a result, such cases are fairly straightforward to assess. With 
nearly every human condition affected one way or another by a genetic influence, most 
diseases, in particular common diseases, are caused or affected by multiple genetic 
influences and environmental factors. For example, there are potentially hundreds of 
genetic loci contributing to type 2 diabetes risk [21]. In order to provide an accurate risk 
assessment and decision support, all relevant genetic loci need to be considered, as well as 
any relevant clinical factors (e.g., age, weight, health history, and comorbidities) and 
environmental influences (e.g., diet, physical activity, stress). Furthermore, it may not 
always be the case that all necessary data are in one central location. Therefore, CDS for 
the WGS must have the capacity to leverage and incorporate several pieces of information 
from multiple genomic and nongenomic data sources. 
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Keep CDS knowledge separate from the variant 
 classification (Requirement #9) 
Masys et al. describe the importance of separating molecular observations (e.g., 
DNA sequence) from variant classification (e.g., pathogenicity classifications) due to the 
need to update variant interpretation as genome knowledge changes and grows over time. 
To illustrate, one study found that over a seven year period, 14.5% of reported variant 
classifications had to be reclassified [22]. Likewise, it is also essential to separate CDS 
knowledge from both molecular observations and variant classification. CDS must have 
the ability to manage evolving and frequently changing gene variant interpretations 
efficiently without requiring changes to the underlying CDS knowledge each time a 
variant's classification changes. Separation of CDS knowledge from variant interpretation 
allows CDS knowledge to be more efficiently handled and maintained. 
 
Have the capacity to support multiple EHR platforms  
with various data representations with minimal  
modification (Requirement #10) 
The reality of the health information environment in the US today is that multiple 
healthcare organizations use multiple EHR and health information management systems 
[23]. Often, these health information management solutions store and represent the same 
health information differently. This can be a challenge when trying to harness the 
information within different health IT systems in different organizations to provide CDS. 
Due to the need to distribute and share WGS enabled CDS knowledge across multiple 
organizations (see next requirement), the CDS architecture would ideally be EHR agnostic, 
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where CDS knowledge can be developed once, and then run consistently anywhere. A 
number of initiatives aimed at supporting this type of architecture are underway, including 
the Health eDecisions initiative, OpenCDS, the SMART platform, and the CDS 
Consortium, to name a few. 
 
Support a large number of gene variants while  
simplifying the CDS knowledge to the  
extent possible (Requirement #11) 
There are roughly 1200 known variants in the adenomatous polyposis coli (APC) 
gene, a gene associated with a rare form of colon cancer [24]. Likewise, there are nearly 
2000 known variants in the cystic fibrosis gene CFTR [25]. Given the potentially high 
number of variants per gene, it may be inefficient to create CDS knowledge for every 
known variant in each disease-causing gene. Furthermore, as novel variants are discovered, 
it will be difficult to update CDS knowledge for every gene variant that is discovered. 
Therefore, to manage this complexity, variants with the same or similar clinical impact 
should be classified accordingly. CDS knowledge can then be simplified by developing 
logic or rules which leverages the variant interpretation rather than the specific variant. 
Nevertheless, in cases where a particular variant has a unique and clinically important 
impact or where machine learning CDS models could utilize individual variants or 
combinations of variants within a single gene, genetic information at the variant level 
should still be accessible to CDS knowledge. In summary, CDS knowledge can be greatly 
simplified by classifying variants into groups of common clinical impact, while still 
supporting inferencing at the individual variant level where necessary. 
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Leverage current and developing CDS and genomics 
infrastructure and standards (Requirement #12) 
Both the CDS and genomics fields have benefited from extensive research and 
development over the years. Indeed, both fields have well developed infrastructure and 
standards to support its uses. Therefore, it is important to leverage these standards and 
infrastructure. Examples include using Human Gene Variation Society (HGVS) and 
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) to represent specific molecular observations; 
American College of Medical Genetics and Genomics (ACMG) recommendations for 
variant classification; HL7 Clinical Genomics standards for the representation of genetic 
information; Arden Syntax, GELLO, GLIF3, GEM, or the HL7 CDS Knowledge Artifact 
Implementation Guide for CDS knowledge representation; the HL7 Decision Support 
Service standard and HL7 Infobutton standard for delivering CDS as a service; and open-
source, standards-based resources such as OpenCDS. While many of these standards and 
resources may not be completely sufficient for meeting the needs of CDS for WGS, it still 
represents significant relevant effort. It will be important to leverage current and 
developing CDS and genomics infrastructure, standards, and knowledge. 
 
Support a CDS knowledge base deployed at and developed by 
multiple independent organizations (Requirement #13) 
With the potential for genomic information to impact nearly every clinical decision 
and the clinical application of genomics rapidly evolving, the time and cost for a single 
entity or organization to manually create and update CDS knowledge will be prohibitive. 
Indeed, no one organization will be able to author and manage all CDS knowledge for all 
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WGS use cases. Furthermore, there must be an efficient and scalable mechanism to 
consistently modify CDS knowledge everywhere it is deployed. Ideally, a standardized 
CDS infrastructure would allow multiple health care organizations, public or private 
entities, or individuals to create, publish, and distribute CDS knowledge efficiently to 
multiple consuming health care organizations. Such an approach will allow a specialized 
entity (e.g., pharmacogenomics experts) to develop and manage CDS knowledge and 
subsequently distribute to 'subscribing' health care organizations. With an ecosystem of 
CDS knowledge developed independently by multiple content developers, it becomes more 
feasible for health care organizations to have affordable access to comprehensive, up-to-
date, and accurate CDS knowledge for the entire genome. 
 
Access and transmit only the genomic information  
necessary for CDS (Requirement #14) 
The separation of CDS knowledge from molecular observations and variant 
interpretations will require relevant genetic information being accessed and sent to a CDS 
engine (or equivalent) for processing. It will be inefficient and insecure to transmit an entire 
genome file for every CDS knowledge. The processing capacity required to transmit and 
sift through an entire genome for CDS knowledge will hinder the ability to provide CDS 
at the point of care in real-time. Furthermore, HIPAA requires that only the minimum 
protected health information needed to satisfy a particular purpose or carry out a function 
be used or transmitted [26]. Therefore, a CDS architecture must only transmit the relevant 




Summary of results 




Summary of findings 
To guide development of CDS for WGS, we identified several additional 
requirements that were not addressed in a previously published work on integrating 
genomic information with EHRs [19].  While the Masys et al. desiderata primarily focused 
on the integration of genomic information within the EHR, this desiderata focuses largely 
on the integration of genomic information with CDS capabilities. The combination of both 
desiderata is important to leverage WGS within EHRs using CDS. 
 
Insights from the community of domain experts 
In general, the community of domain experts provided encouraging and insightful 
comments. The majority of comments for each requirement were largely supportive of the 
proposed requirements, often reiterating the stated importance and occasionally offering 
suggestions on how to accomplish the requirement. Occasionally a participant would 
express doubt that the proposed requirement could actually be accomplished in the current 
health IT environment, even if they had selected the requirement as important. These 
reasons for doubt varied by requirement and expertise. Where appropriate, comments were 
provided to justify one’s opposition to a proposed requirement. In all, the comments were 
very useful in understanding the thoughts and intensions of a participant’s particular 
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responses to the Likert questions. 
While the community of domain experts generally agreed that the proposed 
desiderata were all important, we found some of the feedback interesting. In particular, we 
were surprised by the relative low ranking in importance of desiderata #14 (‘Access and 
transmit only the genomic information necessary for CDS’) compared to the other 
requirements. As this requirement addresses issues of privacy and security, a sensitive topic 
in health care, we did not expect respondents to rank this the least important requirement 
relative to the other requirements. However, in reviewing the qualitative feedback on this 
requirement, we discovered several respondents to be in disagreement that the HIPAA 
‘Minimum Necessary’ requirement would need to be applied in this case. Nevertheless, 
upon consulting with our institution’s health information security experts regarding this 
scenario, they reaffirmed this proposed need to access and transmit only the necessary 
genetic information needed for CDS. Furthermore, while this requirement may be 
important given current technical capabilities, it may be possible that such concerns 
become less important in the future as relevant technologies and technology and laws 
evolve. This possibility could also be reflected in the comparatively lower importance 
rating given to this requirement by the study participants. 
 
Assumptions and implications 
In developing the desiderata we focused on CDS delivered based on well-defined 
knowledge. In other words, we assumed that gene variants and their clinical implications 
were already established. However, there is also a clinical need for genome analysis tools 
such as Omicia Opal, SVBio, and others to support the manual identification of uncommon 
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or novel genetic variants suspected of causing rare phenotypes or orphan diseases [27]. In 
this analysis, we did not focus on this type of genome analysis tool, which could be 
considered a CDS tool, because they will likely not be integrated with routine clinical 
workflow as automatic CDS.   
Another assumption made in developing the desiderata is that the variant 
classification is accurate and consistent between genome variant knowledge bases. In 
reality, variant knowledge bases are known to provide conflicting information, which can 
be problematic, particularly if a genome database is checking several genome variant 
knowledge bases for interpretation. However, as the genomics industry grows and matures 
over time, we anticipate that the quality and collaboration between these variant knowledge 
bases will improve. It is also possible that a centralized variant knowledge base, such as 
ClinVar, will manage all variant classifications [28]. Furthermore, it is important to 
consider the possibility that the same variant shared between two individuals could have 
different variant classifications based upon extrinsic factors. The implication of this 
complexity in variant classification is that the additional decision logic may need to be 
considered when assigning variant classifications.  
Finally, we assumed that WGS data quality is consistent with other methods of 
genetic testing, currently this is not the case [29]. Often if a pathogenic variant is identified 
with a WGS test, the variant is confirmed using more reliable genetic testing such as Sanger 
sequencing [30]. Improvements in data quality will be necessary before WGS testing can 
be used as a stand-alone genome assessment method in the clinical setting. However, we 
also anticipate that current and future developments of sequencing technology and 





Desired capabilities and correspondence to desiderata 
There is much debate regarding the laboratory’s role in recontacting a treating 
clinician each time a variant classification changes [31,32]. For some, the ability to alert 
treating clinicians to changes in variant classification, particularly from an unknown or 
benign classification to a pathogenic one, is an important responsibility. Indeed, this 
capability is the premise behind the GeneInsight software [22,33]. With regards to this 
study, alerting to changes to variant classification is built into the CDS functions 
represented by desiderata #9 and #11. Every time CDS is triggered, it can re-assess the 
variant classification and utilize the most recent classification available that time. One 
would not necessarily need to alert a clinician when a variant classification changes; rather, 
CDS knowledge could periodically check the patient’s genome and provide the new 
interpretation and recommendations within the workflow, as necessary. 
Furthermore, presentation of CDS results and recommendations to clinicians in an 
understandable and actionable way is another desirable capability. There is much research 
and efforts already underway in this space.  The incorporation of best practices identified 
in this manner can be considered an additional aspect of desiderata #12 (‘Leverage current 
and developing CDS and genomics infrastructure and standards’). 
 
Strengths and limitations 
A major strength of this study is the development of the proposed desiderata by a 
diverse core panel of domain experts and the subsequent validation among a larger group 
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of domain experts. In particular, we invited groups with participants who (1) have 
experience developing and deploying CDS systems, and/or (2) are involved with the 
clinical application or interpretation of genomic information in health care.  Another 
strength of our approach is the relative ranking of the desiderata, which provide some 
guidance on the relative importance of supporting these desired features when developing 
CDS capabilities for WGS information. 
A shortcoming of the study is the use of a pragmatic research design. Specifically, 
this study only assessed community input once, as compared to multiple rounds of 
feedback in methods such as the Delphi method [34]. However, as this survey was 
anonymous and contact information was not provided by most participants, it was not 
feasible to have multiple rounds of input from the community domain experts. 
Nevertheless, the core panel did conduct iterative rounds of revisions based on the 
community experts’ input.  A second limitation of this study is that we only asked for the 
importance of desiderata, whereas we could have asked for additional information, such as 
feasibility and current availability.  However, we felt that perceived need was of greatest 
importance.  Also, we wished to maximize broad participation by keeping the survey 
relatively simple and short.  Therefore, we believe the utilized study design maximized the 
amount of useful information obtained from the community of domain experts. 
Another potential shortcoming is that we did not explicitly solicit participation from 
additional professional networks with expertise in this domain, such as the Electronic 
Medical Records and Genomics (eMERGE) Network and Pharmacogenomics Research 
Network (PGRN). However, we believe that the personal and professional networks used 
in this study constitute several individuals belonging to eMERGE, PGRN, and other 
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groups. Additionally, we received a large enough representative sample size from the 
participating networks and qualified individuals, such that additional participants would 
likely not have changed the results significantly.   
 
Future direction 
Given the important need to provide CDS capable of supporting WGS information 
at the point of care, and the requirements to support both the Masys et al. and these 
desiderata, a novel CDS architecture capable of supporting these requirements will need to 
be designed, developed, and evaluated. Due to the scope and complexity of integrating 
WGS information with CDS as outlined in the desiderata, we propose a CDS architecture 
that utilizes principles of a service-oriented architecture (SOA). SOA is a software design 
methodology based on a collection of separate, independent software components known 
as services, which are self-contained and have well-defined capabilities [35]. Accordingly, 
we are currently developing a prototype CDS architecture that is based on the principles of 
SOA and is capable of supporting WGS information in a manner consistent with the 
desiderata described in this manuscript and the Masys et al. paper. Once such a prototype 
is developed and tested, clinical scenarios will test the feasibility of this approach. Finally, 
once testing is complete, implementing as a pilot study will be important to validate the 
solution in a real clinical setting. As a result of these efforts, it is likely that additional 
requirements may be identified for inclusion in the desiderata. As such, this proposed set 
of desiderata should not be considered a final authoritative set, but rather a foundation upon 





CDS to support WGS information at the point of care will likely be necessary to 
meet the clinical demands of the genome. However, the complexity of WGS information 
will require an approach for implementing CDS that is flexible and robust. We have added 
and validated several additional requirements to the Masys et al. desiderata which 
specifically focus on CDS needs for WGS information. We speculate that these additional 
desiderata will benefit the design and development of CDS approaches for supporting the 
full integration of WGS information into clinical care. 
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Figure 3.1: Potential examples of CDS leveraging WGS data 
 
 
Figure 3.2: Desiderata for the integration of genomic data into EHRs 
described by Masys et al. 
  
1. Maintain separation of primary molecular observations from the clinical 
interpretations of those data  
2. Support lossless data compression from primary molecular observations to clinically 
manageable subsets  
3. Maintain linkage of molecular observations to the laboratory methods used to 
generate them  
4. Support compact representation of clinically actionable subsets for optimal 
performance 
5. Simultaneously support human-viewable formats and machine-readable formats in 
order to facilitate implementation of decision support rules  
6. Anticipate fundamental changes in the understanding of human molecular variation  
7. Support both individual clinical care and discovery science 
CDS type    Clinical genomics example 
Medication dosing support CDS automatically adjusts warfarin dosing as a result of 
known alleles in the VKORC1 and CYP2C9 genes. 
Order facilitators An order for colonoscopy is recommended at a younger 
age as a result of known pathogenic mutations in genes 
associated with colon cancer. 
Alerts and reminders During medication ordering, gene variants known to affect 
drug pharmacokinetics are checked and clinicians are 
alerted to potential gene-drug interactions. 
Relevant information display Context aware infobuttons in the problem list leverage 
genome data to provide genetic risk information for a 
patient with breast cancer. 
Expert systems The EHR provides a 10-year cardiovascular disease risk 
score based on clinical, environmental, and genetic risk 
factors. 
Workflow support The EHR schedules a genetic counseling consultation 
during prenatal visit due to presence of an X-linked 





Figure 3.3: Additional desiderata for the technical integration of  




Figure 3.4: The proportion of each survey response for 
all requirements in the desiderata 
  
8. CDS knowledge must have the potential to incorporate multiple genes and clinical 
information. 
9. Keep CDS knowledge separate from variant classification. 
10. CDS knowledge must have the capacity to support multiple EHR platforms with 
various data representations with minimal modification. 
11. Support a large number of gene variants while simplifying the CDS knowledge to 
the extent possible. 
12. Leverage current and developing CDS and genomics infrastructure and standards. 
13. Support a CDS knowledge base deployed at and developed by multiple 
independent organizations. 








A PROPOSED CLINICAL DECISION SUPPORT ARCHITECTURE  




The use of whole genome sequence (WGS) information for routine clinical care 
will greatly enable the possibilities of personalized medicine, which include (1) improving 
diagnostic accuracy and disease characterization, (2) targeting therapies to individuals, (3) 
identifying and preventing disease among high-risk individuals, (4) improving healthcare 
efficiency, and (5) reducing unnecessary costs [1,2]. With genomic information readily 
available to clinicians at the point of care, many of these goals can be realized. Indeed, 
significant investment has been made to improve genome sequencing technology and 
reduce sequencing costs, making it easier to obtain a patient’s WGS for clinical care [3]. 
As a result, WGS information is now being used in the clinical setting for rare, undiagnosed 
disorders [4–7]. If current trends continue, it is anticipated that WGS information will soon 
be available for routine clinical care, thus enabling personalized medicine on a widespread 
                                                          
2 Reprinted with permission of Welch BM, Loya SR, Eilbeck K, Kawamoto K. A Proposed Clinical 




scale [8].    
While this is an intriguing prospect for patients, clinicians, and researchers, 
significant barriers exist which may hinder the effective use of WGS information in a 
routine clinical care setting. These barriers include (1) static laboratory reports intended 
for human consumption, (2) the complexity of genetic analysis, (3) limited physician 
proficiency in genetics, and (4) the lack of genetics professionals in the clinical workforce 
[9]. These barriers, if not overcome, will likely hinder the ability of clinicians to provide 
personalized medicine using WGS information. Although there may be several approaches 
to overcome these barriers, we believe clinical decision support (CDS) provided within the 
clinical workflow provides the greatest opportunity to enable effective use of WGS 
information in a routine clinical setting [9,10].     
CDS entails providing clinicians, patients, and other healthcare stakeholders with 
pertinent knowledge and/or person-specific information, intelligently filtered or presented 
at appropriate times, to enhance health and health care [11]. Examples of CDS include 
medication dosing support, order facilitators, point of care alerts and reminders, relevant 
information display, expert systems, and workflow support [12]. Research on CDS has 
been conducted for several decades with established literature defining features that 
contribute to successful CDS interventions [13,14]. To be effective, it is essential that CDS 
for WGS information follow these proven CDS practices and approaches; in particular, the 






State of the art 
While CDS research is a well-established field, research on CDS for genetically-
guided personalized medicine is a much younger, but growing, field. In a systematic review 
of CDS interventions for genetically-guided personalized medicine, Welch and Kawamoto 
identified 16 primary research articles describing CDS interventions using genetic 
information between 1990 to 2011 [15]. The majority of these CDS interventions tended 
to be stand-alone applications, which required re-entry of a patient’s clinical and genomic 
data by a clinician. Furthermore, these applications were largely limited to a single, or 
limited number, of genes (e.g., BRCA) [16]. Recently, Tarczy-Hornoch et al. conducted a 
review of clinical reporting approaches for WGS (and whole exome) information in the 
EHR, which are currently implemented at six healthcare organizations [17]. These 
healthcare organizations developed, implemented, and managed various approaches to 
EHR integration and CDS. However, the majority of these approaches were limited to static 
PDF reports (similar to pathology reports), and only two organizations leveraged active 
CDS capabilities of the local EHR. The authors acknowledge that active CDS will be 
necessary for WGS information and that more sophisticated informatics tools will be 
necessary to scale up to meet the challenges of WGS information [17]. A more detailed 
description of these CDS examples and how they compare to the work described in this 
manuscript can be found in the Discussion section. In general, literature on CDS for WGS 







Given the critical role health IT will play in overcoming the barriers of WGS 
information and the specific challenges inherent in using genomic information, Masys et 
al. developed a technical desiderata for the integration of genomic information with an 
EHR [19]. These requirements, which were developed by a panel of experts, illustrate 
important considerations that should be addressed when developing health IT applications 
capable of supporting genomic information (see Figure 4.1). Indeed, these desiderata are 
intended to overcome many of the barriers and challenges (also described in the Masys et 
al. manuscript) of using genomic information for clinical care.   
While the Masys desiderata provide a strong framework for integrating genomic 
data with the EHR, additional requirements are desirable for the integration of genomic 
information with CDS. Indeed, we believe it will be essential that genomic data are not 
only available within the EHR, but provided in a way that is useful to clinicians through 
CDS [9]. To address this need, Welch et al. developed an additional desiderata, to augment 
the Masys et al. desiderata, specifically focused on the integration of genomic information 
with CDS (see Figure 4.2) [20]. This work also describes the barriers and challenges that 
these additional requirements attempt to address. 
These additional desiderata, when used together with the Masys et al. desiderata, 
can provide a foundation to guide research and development on CDS for WGS information. 
As there are many barriers inherent in leveraging WGS information for CDS [9], 
incorporating these desiderata into the design and development process may help system 





Given the importance that CDS will play in realizing personalized medicine 
through WGS information, and the early stage of research and development in this domain 
[15,17,18], we put forth a theoretical CDS architecture based upon the technical desiderata 
and approaches utilized in prior work [15,17]. Indeed, this manuscript lays out the 
conceptual design of a proposed architecture and describes how each component of the 
architecture attempts to meet the requirements described in the technical desiderata. It is 
our intent to put forward this proposed architecture as a foundational reference for research 
and development on CDS for WGS information in the future. 
 
Methods 
We have leveraged our collective experience in the domains of genetics, 
bioinformatics, and clinical informatics to propose a CDS architecture capable of 
supporting WGS information at the point of care. This manuscript, while describing the 
need for a particular approach or components, does not attempt to define the architecture 
components in sufficient detail necessary for implementation. Rather, this manuscript 




Given the complexity of WGS information, the success of CDS in the genomic age 
will likely require an architecture that separates key capabilities into independently 
managed component parts [21]. As such, we advocate the use of a service-oriented 
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architecture (SOA) as a design principle for our proposed CDS architecture. SOA is a 
software design methodology based on the interaction of separate, independent software 
components, known as services [22]. A service is a self-contained component which has 
well-defined, understood capabilities. SOA supports the reusability and standardization of 
processes, allowing for independent evolution and modifications to a particular service, 
reducing the burden of change on the overall system [23]. Because of the vast number of 
disparate health IT systems, the application of SOA principles offers several benefits to 
health care [24]. Indeed, research and development on SOA for CDS has led to several 
health IT standards and applications [25–28]. Furthermore, SOA-based CDS is currently 
under consideration for EHR certification criteria related to Stage III Meaningful Use 
guidelines [29]. 
 
SOA CDS for WGS information 
While SOA offers many benefits to health IT and CDS, we believe it will be 
necessary for WGS-enabled CDS [21]. Indeed, SOA can provide the agility needed to keep 
up with the rapidly evolving genomics knowledge base [30]. Furthermore, SOA allows for 
the scalability that is needed to handle the breadth of genomic applications in health care, 
particularly across multiple independent health care organizations [31]. In contrast, were a 
health care organization to develop and maintain their own CDS knowledge for WGS 
information, they could become overwhelmed by the time and cost of creating, managing, 
and updating the CDS knowledge base for the entire genome [32]. This would be 
particularly challenging for the majority of health care organizations that have a limited 
clinical genomics presence [33]. Indeed, we believe it would be prudent to separate key 
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components into independently managed services, which can be optimally maintained by 
third-party organizations.  
A SOA-based CDS architecture for the WGS information is an extension of 
previous efforts on SOA-based CDS in general [28] and early examples of CDS for genetic 
information [34–36]. The services and components required in our proposed architecture 
consist of genome sequencing and annotation, genome databases, genome variant 
knowledge bases, CDS knowledge base, CDS controller, and the EHR (see Figure 4.3). A 
glossary of terms and brief descriptions is available in Appendix C. While some of these 
services and components are already available, some will need to be developed or enhanced 
to support a SOA-based approach. In subsequent sections of this manuscript we describe 
each component in further detail, how they interact with each other, and enhancements that 
may be necessary. 
 
Genome sequencing and annotation pipeline 
The first step in the entire process is to obtain the patient’s genome sequence, for 
either the whole genome, the exome, a gene panel or a more targeted, smaller subset of the 
genome. For a whole genome sequence, when compared to a reference genome, there are 
roughly three million single nucleotide variants per comparison. Two file formats for 
representing a patient’s set of genome variants include the variant call format (VCF) and 
genome variant format (GVF) [37,38]. Both formats are able to represent various sequence 






Once the variants in the genome have been identified, it is necessary to prioritize 
variants that may have relevant phenotypic impacts. There are several sequential steps to 
variant annotation, which is referred to as the ‘annotation pipeline.’ Initially, this process 
identifies variants occurring within known or predicted genes, regulatory regions, protein 
coding sequences, or splice sites. Variants which occur within genes are assessed for 
clinical impact using curated genome variant knowledge bases, such as the Human Genome 
Mutation Database (HGMD), Online Mendelian Inheritance in Man (OMIM), ClinVar, and 
other locus-specific mutation databases [39–42]. Additionally, computational 
interpretation approaches such as Variant Annotation, Analysis & Search Tool (VAAST), 
SIFT (http://sift.jcvi.org/) and Polymorphism Phenotyping (PolyPhen) can be employed to 
predict variant pathogenicity based upon the impact on the gene’s translational product 
[43–46]. Finally, gene functions, links to external knowledge resources, and other variant 
metadata can also be included. The annotation pipeline can be developed internally by the 
organization sequencing the patient’s genome or using a service provided by a private 
company specializing in genome annotation services [47–49]. Currently, the entire 
sequencing and annotation pipeline is typically managed by a pathology laboratory. 
However, as genome sequencing technology advances, some speculate that this process 
could occur in the clinic [50]. In such cases, the proposed CDS architecture could still 
support this approach as long as this component interacts, in a similar way, with the other 





Genome variant knowledge base 
A key part of the genome annotation process is to identify genome variants and 
assign a clinical impact, if known. A genome variant knowledge base is a repository of 
known genome variants and associated clinical interpretations of that variant. During the 
annotation pipeline, genome variant knowledge bases are ascertained for pre-existing 
knowledge on variants. There are many types of genome variant knowledge bases, which 
include (1) privately-controlled knowledge bases, such as the Human Gene Mutation 
Database (HGMD) [39]; (2) open access, locus-specific knowledge bases, such as those 
created using the Leiden Open Variation Database (LOVD) [42]; (3) proprietary 
knowledge bases, typically owned and managed by genetic testing laboratories, who 
maintain exclusive access [51]; and (4) publicly available, centrally-managed repositories, 
such as ClinVar [41]. Typically, when a new variant is discovered, or new information 
about a known variant is made available, this information will be recorded in one or more 
of these knowledge bases. Furthermore, curators may monitor publications and reports in 
order to update a knowledge base accordingly. 
ClinVar, which is a publicly available central resource managed by the National 
Library of Medicine, represents a model wherein genome knowledge bases and 
laboratories (described above) can upload their expertly curated knowledge into one 
location. Previously, genome annotators may have had to use several different genome 
variant knowledge bases and pay to access particular knowledge. Furthermore, with a 
participatory approach to genome variant annotation, ClinVar may become a more robust 
and extensive knowledge base than any single locus-specific or laboratory-managed 
knowledge bases. Open access, locus-specific knowledge bases tend to be curated and 
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maintained on a volunteer basis, making the knowledge available limited. While 
laboratory-managed knowledge bases contain the best variant knowledge, they are also (1) 
limited by the number of unique variants observed by that laboratory and (2) may have 
tightly controlled access to the variant knowledge in order to maintain a competitive 
advantage over other testing laboratories [51]. Nevertheless, if ClinVar is embraced by the 
diagnostic laboratory community with the support of the ClinGen effort [52], the laboratory 
knowledge bases will likely serve as one of the most important sources of variant 
annotations. 
 
Variant clinical interpretations categories 
The clinical interpretation categories for sequence variations stored in the genome 
variant knowledge bases may follow recommendations set by the American College of 
Medical Genetics and Genomics (ACMG) and others [53,54]. The ACMG 
recommendations include classifications such as ‘pathogenic,’ ‘likely pathogenic,’ ‘variant 
of unknown significance (VUS),’ ‘likely benign,’ and ‘benign’ for diseases caused by 
genes. Pharmacogenomics (PGx) classification categories include such as ‘ultrarapid 
metabolizer,’ ‘intermediate metabolizer,’ and ‘poor metabolizer’ for genes impacting drug 
metabolism [55]. Some have also used allele classifications (e.g., *1/*2) to represent PGx 
variants for CDS, though this practice is becoming increasingly complicated as more 
variants are discovered [56]. Unfortunately, many of these classification categories are not 
used consistently and many labs create their own classification categories, which may 
result in interpretation discrepancies and confusion among clinicians. Therefore, in order 
to facilitate widespread adoption of CDS, future effort may be necessary to promote 
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standardized variant classification definitions [57]. 
 
Variant knowledge management 
Our understanding of genomics in health is still relatively nascent. However, as 
research into the human genome grows, so too will understanding of health impacts of 
genome variants. This growth in understanding will likely lead to frequent and significant 
changes to variant classifications. To illustrate, over a seven year period, the Partners 
HealthCare Center for Personalized Genetic Medicine’s Laboratory for Molecular 
Medicine genome variant knowledge base, managed by the GeneInsight Suite, reclassified 
nearly 15% of their original classifications, with almost one-third of those initially being 
VUS [30]. As such, genome variant knowledge bases will play an important role in 
independently managing the clinical interpretations of variants for the genomic CDS 
architecture. Not only can the most up-to-date variant classification be available during the 
annotation process, but if a clinical interpretation of a variant later changes, the variant 
classification for a particular patient’s genome can be automatically updated. In such cases, 
changes in clinical interpretations will likely need to be versioned and tracked to account 
for potential liability concerns. Nevertheless, this separation of concerns through the SOA 
allows CDS to use the most up-to-date variant knowledge, while being free of 
dependencies that are timely and costly to update.   
 
Genome databases 
The storage of a patient’s annotated genomic sequence is central to the proposed 
CDS architecture. With a patient’s genome stored and accessible, a patient’s genetic 
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information can be available for CDS when needed. 
 
Genome data considerations 
Although the size of a genome data set can be significantly reduced using variant 
file formats, much of the resulting data may still be unnecessary for most CDS use cases 
[9]. For example, these genome variant files contain a comprehensive set of all variants in 
the patient’s genome, whether or not they are associated with a known gene or phenotype. 
As such, it may be unnecessary to make all variants available for CDS, particularly those 
which have no known association with genes and or phenotypic impact. Furthermore, while 
genome sequence metadata and annotations are important for quality assurance, variant 
classification, and versioning, some of this metadata may not be necessary for the purposes 
of CDS. Examples of this metadata include the reference sequence used, sequence 
coverage, population frequency, and reference copy number.  
These examples are important to consider when trying to simplify CDS knowledge 
to the extent possible. To illustrate, in cases where there are hundreds of known pathogenic 
variants within a particular gene, it may not be efficient to write CDS knowledge for every 
known variant, particularly when the clinical phenotypes of different variants are identical 
and variant clinical interpretations can change. In certain use cases it may be sufficient to 
simply represent a variant by its clinical interpretations. For example, a simple CDS rule 
using this approach could be: “If [gene=‘MLH1’] has [variant classification=‘pathogenic’], 
then [recommendation=‘recommend colonoscopy to patient’].” Nevertheless, for specific 
use cases where the variant location and effect (e.g., frameshift mutations) within a gene 
produces a unique phenotype, or when a particular allelic variant is important for 
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As a result, for the purposes of CDS we advocate the use of a clinical genome 
database consisting of only a patient’s clinically relevant variants and a full genome 
database consisting of all variants and genome metadata. The clinical genome database 
should consist primarily of variants in or near genome regions associated with phenotype 
(e.g., genes), with associated data elements required for CDS knowledge. Data elements 
and possible standards which could be used for CDS include (1) genome type (e.g., 
germline or somatic); (2) gene name in the standard Human Genome Organisation 
(HUGO) Gene Nomenclature Committee (HGNC) format [58]; (3) variant in a standard 
format, such as the Human Gene Variation Society (HGVS) format [59]; and (4) variant 
clinical classification, as provided by the genome variant knowledge base. Other 
potentially important elements that could be useful for CDS include genotype, haplotype, 
tissue type, and genome copy number.  However, it is currently unknown exactly which 
genomic information will be necessary for CDS; future research will help determine which 
information is important.  
Other reasons for creating a simplified clinical genome database are to improve 
performance and security. In a SOA architecture with multiple independent components, 
speed and efficiency are a top priority, particularly for CDS. Reducing the need for a 
database query to filter through unneeded data is likely to improve performance, 
particularly when such databases grow to include genomes of many patients. Furthermore, 
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limiting genetic information available to external queries promotes privacy and security, 
as clinically unnecessary genomic data could potentially be used to uniquely identify 
anonymous genomes [60].  
Finally, while we describe the two databases as being separate, this can be a virtual 
separation or a physical separation. Nevertheless, there will need to remain a connection 
that will allow for changes in our understanding of the human genome. Indeed, data 
available in the full genome database will be available to the clinical genome database if 
and when they become clinically relevant and useful to CDS. Furthermore, just as a 
genome database is made available for clinical care, it should also be available for research, 
using many of the same service-based approaches [21]. 
 
The roles of the electronic health record 
The EHR represents an important role in the proposed architecture, as it is 
responsible for collecting and storing the patient’s clinical data required for CDS. 
Furthermore, it provides the mechanism by which CDS interacts with the end-user at the 
point and time of care. Indeed, to be effective, CDS for WGS should be integrated within 
the EHR clinical workflow, similar to how other nongenomic CDS is provided. It will 
likely not be sufficient or desirable to have a stand-alone CDS application for WGS 
information. 
 
EHR as a repository of clinical data 
EHRs serve as the primary source of collecting and storing clinical information that 
will be used to provide CDS. While EHRs have traditionally functioned as clinical data 
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repositories, most EHRs currently do not have an effective way of storing genetic 
information [61]. Furthermore, with competing higher-priority demands (e.g., Meaningful 
Use) among EHR vendors, this may not change in the near future. Therefore, our approach 
is to store genomic data separately from the clinical data in the EHR, and leverage service-
based capabilities to obtain the clinical and genomic data required for CDS. This approach 
reduces the burden on EHR developers to build genome-specific capabilities, while 
allowing them to continue serving as the primary source of clinical data. Unfortunately, 
most EHRs use their own approaches for collecting and storing clinical data, which can be 
challenging for scalable CDS solutions [62]. However, this challenge can be overcome by 
mapping various data models to a common standardized data model, used specifically for 
CDS. A CDS data model being considered for EHR certification criteria related to 
Meaningful Use Stage 3 is the Health Level 7 Virtual Medical Record (vMR) standard 
[63]. 
 
CDS interface with end users 
In addition to collecting and storing clinical data, EHRs are also responsible for the 
triggering of a CDS request and then presenting the CDS results in an effective way to end 
users. CDS can be triggered in a variety of situations, such as when (1) the patient’s record 
is opened or a certain EHR view is selected, (2) a drug or procedure is ordered, (3) clinical 
documentation occurs within the EHR, or (4) at a routine time interval. Furthermore, the 
EHR can present CDS results within the clinical workflow of the clinician [14]. To this 
end, CDS results can be displayed as point of care alerts or reminders, relevant information 
displays, care recommendations, order facilitators, or workflow support [12,64]. In 
78 
 
principle, all the same CDS capabilities, which are currently available within EHRs, should 
also be used to trigger and present CDS for WGS information according to CDS best 
practices [13,14]. 
 
Leveraging available EHR capabilities 
To provide CDS for WGS information within the EHR, the proposed architecture 
should primarily rely on EHR capabilities that are currently supported, or likely to be 
supported in the near future. To illustrate, the EHR market currently consists of hundreds 
of vendor solutions, each with their own development roadmaps and timelines [65]. Being 
reliant on custom EHR integration solutions may be an inadequate approach to attaining 
widespread and consistent use of CDS for WGS information [35]. Rather, aligning the 
proposed CDS architecture with current and potential future EHR capabilities, mandated 
by certification criteria, offers a pragmatic and effective solution. Of note, service-based 
CDS capabilities for EHRs are currently under consideration for Meaningful Use Stage 3 
[25]. Moreover, some major EHR system vendors already support service-based CDS 
capabilities [66].  
In summary, there are many advantages to leveraging EHR capabilities that are 
currently available and/or are aligned with relevant EHR certification criteria for WGS-
driven CDS. As this approach is not dependent upon internal EHR development timelines 
and prioritization, it offers a greater chance of gaining widespread and consistent 
distribution across multiple EHR vendors and healthcare organizations. As such, this 
proposed architecture is designed to leverage existing EHR capabilities and align with 
ongoing developments in health IT. 
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CDS knowledge base 
CDS entails providing person-specific care recommendations or knowledge, which 
can be used to enhance health and healthcare [67]. CDS knowledge bases contain 
representations of clinical knowledge (CDS knowledge) in the form of logic, decision 
rules, expressions, guidelines, and algorithms which support the provision of care, based 
upon a patient’s clinical and genomic information. In a SOA CDS architecture, the CDS 
knowledge base is encapsulated as an independent unit by a service. This service receives 
patient-specific information provided by the CDS requester, processes this information, 
and returns a CDS result. As such, this approach reduces dependencies upon requesting 
EHR systems (requestor), if standardized data models and terminologies are used [68]. 
Furthermore, as the CDS knowledge is agnostic to how or where the data are originally 
stored, its primary concern is to process the standardized patient data according to the 
knowledge it contains.  
Likewise, as CDS knowledge authoring and maintenance can be time consuming, 
keeping the maintenance of variant classifications separate from CDS knowledge will 
promote efficiency in CDS knowledge management. This approach allows variant 
classifications to freely change without needing to update CDS knowledge bases as well. 
Finally, as CDS knowledge could become complicated for genomic information, 
simplifying the knowledge to the extent possible is a desirable attribute. As described 
previously, this can be achieved by writing CDS knowledge using a gene and an associated 
clinical interpretation. Creating CDS knowledge for every possible variant within a 
particular gene, for which there are thousands of variants known and potentially many more 
unknown, will be inefficient [9]. 
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CDS knowledge development and management 
As a result of the SOA approach, CDS knowledge bases can be deployed and 
maintained by an independent entity specializing in the development and management of 
CDS knowledge. For example, an entity that specializes in developing and optimizing 
pharmacogenomic dosing regimens can deploy their knowledge as a service-based CDS 
knowledge base, allowing subscribing organizations to leverage the most up-to-date 
knowledge, provided by that entity [69]. Likewise, medical societies, which develop 
disease-specific care guidelines and recommendations, can deploy their work as a CDS 
knowledge base and allow member institutions to utilize the care guidelines and 
recommendations in the form of CDS [70]. Furthermore, the ability to leverage 
independently developed CDS knowledge could increase a health care organization’s 
access to CDS capabilities, and promote competition among CDS knowledge authors. 
Similarly, this SOA approach also supports the ability to share the same CDS knowledge 
among many health care organizations. This is important because it is unlikely that a single 
healthcare organization will be able to maintain all its own CDS knowledge for WGS 
information, particularly for small and rural healthcare organizations with limited 
genomics expertise [9]. 
 
CDS controller 
As previously described, genomic data required by the CDS knowledge base will 
not be stored with the clinical data from the EHR. Rather, a patient’s genomic information 
will be stored and maintained in a separate genome database [21]. With the separation of 
clinical data from genomic data as proposed in this CDS architecture, a component which 
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links and coordinates the other components of the architecture together, will be required.  
Indeed, this is the primary role of the CDS controller, which is to combine clinical data 
from the EHR with genetic data from the clinical genome database into a complete data 
package for the CDS knowledge base. The CDS controller compares the received patient 
data to the CDS knowledge data requirements, which can include required data elements 
and desirable formats. The CDS controller can also facilitate workflow-appropriate 
triggering, perform terminology mappings, exclude unneeded clinical data, request 
additional data from other sources, and enable end-user interaction, as necessary [26]. The 
functions of a CDS controller, in our proposed CDS architecture, consists of the following 
sequential steps: 
1. The CDS controller obtains clinical data from the EHR in a standardized 
format (e.g., vMR), as a result of a CDS trigger within the EHR.  
2. The patient data are compared with the data requirements for the requested 
CDS knowledge module. In the case of our architecture, the CDS controller 
will identify that the patient’s genomic information required by the CDS 
knowledge is missing, and will make a request to the genome database for 
that information.  
3. The CDS controller obtains the patient’s genomic information from the 
clinical genome database, as specified by the CDS knowledge data 
requirements. 
4. The CDS controller then merges the patient’s genome information with the 
clinical information into a single vMR file.  
5. The complete data package is subsequently transmitted to the CDS 
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knowledge base for evaluation. 
6. After CDS evaluation, the CDS controller receives the CDS response from 
the CDS knowledge base. At this point, the CDS controller can then process 
the CDS responses with additional workflow requirements (e.g., human 
review and approval of CDS recommendation), if necessary.  
7. The CDS response is relayed to the EHR for end-user presentation.  
While the CDS controller is described as being a separate component in this 
architecture, it is certainly feasible for the CDS controller to be an embedded function 
within an EHR. Indeed, such a scenario is described in another manuscript [28]. 
 
Genome interpreter 
The genome interpreter, while not directly involved with CDS as described above, 
may be an important component to clinicians who desire to manually review variants in a 
patient’s genome. As CDS may not be able to represent every possible clinical scenario, 
the capacity to manually review variants, clinical impact, and relevant metadata about a 
patient’s genome will be important. Examples of genome interpreters include those 
provided by commercial genome annotation companies [47–49]. While these solutions are 
available as stand-alone applications, ideally they should be made available to clinicians 








Achieving the EHR and CDS WGS desiderata 
An objective of the proposed CDS architecture for WGS information is to satisfy 
the requirements in the technical desiderata [19,20]. Table 4.1 represents a summary of 
barriers to using WGS information in the EHR and CDS, the desiderata requirements that 
are designed to address the barrier, and a description of how our proposed architecture 
attempts to satisfy each requirement in order to overcome the barrier. 
 
Discussion 
Comparison of proposed architecture to prior 
work on CDS for genomics 
As described in the introduction, there is a growing research base on CDS 
interventions for genomics [17]. Indeed, the design and capabilities of many of these CDS 
examples provide the basis for the conceptual approaches described in our proposed 
architecture. As described earlier, of the organizations described in the Tarcy-Hornoch et 
al. review [17], all organizations developed and managed their own genome annotation 
process, each developed custom genome variant knowledge bases, and most had primitive 
CDS capabilities, primarily limited to PDF reports. Furthermore, report generation was 
dependent upon local experts unique at each institution, an approach that is unlikely to be 
scalable. 
As a noteworthy example, the GeneInsight Suite is a stand-alone, Web-based 
interface designed to manage and communicate genome variants and clinical 
interpretations between clinicians and laboratories [30,34,77]. The GeneInsight Suite is an 
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example of an application that can support genome variant knowledge base managed by a 
laboratory, and maintain current clinical interpretations in a genome database. While this 
application focuses on managing variant knowledge and communicating updates to 
clinician end-users, the knowledge communicated is largely limited to the patient’s 
genomic information, variant clinical interpretation, and a generic variant report. 
Furthermore, as the application currently exists separately from the EHR, its ability to 
leverage clinical data and provide patient-specific CDS based on clinical and genomic data 
within the EHR workflow, is limited [9]. Indeed, tighter integration with the EHR and CDS 
is an important future effort acknowledged by the developers of the GeneInsight 
application [30]. 
Furthermore, several groups have implemented preemptive pharmacogenomics 
(PGx) CDS within EHRs, namely the PREDICT (Pharmacogenomic Resource for 
Enhanced Decisions in Care & Treatment) project at Vanderbilt in Nashville, Tennessee 
[35,78]; a group at St. Jude Children’s Research Hospital in Memphis, Tennessee [79,80]; 
and the CLIPMERGE (Clinical Implementation of Personalized Medicine through 
Electronic Health Records and Genomics) project at Mt. Sinai Hospital in New York City 
[36]. The PREDICT project provides an example of active CDS for genotype information 
that is integrated within the clinical workflow of the EHR. Indeed, this CDS capability for 
PGx is built into the order entry component of Vanderbilt’s homegrown EHR system. 
Furthermore, all genotype results for a patient are stored in database repository, separate 
from the EHR, with actionable genotype results and their interpretations stored as a 
laboratory result within the EHR. As the CDS for this project was developed and built into 
the EHR by an internal panel of experts, its scalability is limited beyond their own 
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institution. Furthermore, the CDS rules do not incorporate clinically relevant non-genomic 
information into the decision process [35,78].  The St. Jude Children’s Hospital also takes 
an approach of storing genetic test results directly in the EHR (Cerner). The EHR uses its 
native CDS capabilities to provide alerts and recommendations, which are developed and 
maintained by the institution. Again, this approach will likely be challenging to scale 
beyond their institution and beyond the PGx use case. Finally, for the CLIPMERGE 
project, actionable PGx genetic test results derived from institution’s research biobank 
(BioMe) are combined with relevant clinical information extracted from the institution’s 
EHR (Epic) in an external CLIPMERGE database. An external CDS rules engine also 
processes the patient data from the database and returns the results back to the EHR in real-
time. The CLIPMERGE approach uses a separation of components and is likely the closest 
example to the approach described in the current manuscript. However, with clinical data 
extracted from the EHR and stored in a separate database along with the genetic 
information, it is also unclear if this approach could support WGS information and whether 
it can be easily scalable [57]. 
 
Originality and uniqueness of the proposed architecture 
In summary, these examples represent important contributions to CDS approaches 
for genomics. While not all these solutions are designed for WGS information, and some 
of these approaches would struggle to support WGS information, they contain important 
design approaches that can be implemented in a scalable architecture, able to support WGS 
information. Indeed, many of the design principles in these examples were a source of 
inspiration and adopted for our proposed CDS architecture. Indeed, we believe it will 
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require the coordination of several of these proven components to build a CDS architecture 
capable of effectively leveraging WGS information. As a result, we have proposed an 
architecture, which uses many of these proven design approaches, that is able to provide 
CDS for WGS information on a widespread scale. We believe that our proposed 
architecture approach, described in this manuscript, will be important to achieving this 
goal. 
 
Barriers still to overcome 
While the proposed architecture aims to overcome many barriers related to genetic 
information, there are still many barriers to overcome before this architecture can be 
realized on a widespread scale. For instance, our understanding of the human genome and 
thus the annotation process is still in the relatively early stages. In fact, the reference 
genome used during the annotation process will likely change in the future. Likewise, many 
caveats such as race and family health history must be considered for an accurate clinical 
interpretation of a variant. Furthermore, as described earlier, many variant classification 
categories are used to describe the clinical impact of variants. As these classifications may 
be used when authoring CDS knowledge, it is important that a standard, well defined 
variant classification system is consistently used to describe a variant’s clinical impact. 
While ClinVar has a set of classifications that are currently used [81], they are probably 
not sufficient to represent clinical impact with the specificity needed. Furthermore, with 
regards to ClinVar, there may be situations that arise involving differing expert 
interpretations for the same variant. In such cases, the various interpretations will have to 
be harmonized in some way by ClinVar or a related entity.  
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With regards to CDS infrastructure, service-based CDS capabilities are still in the 
early stages of industry adoption and thus still fairly limited with regards to technical 
capabilities, available standards, and available CDS knowledge. Indeed, using the SOA 
CDS approach described herein will require that significant gaps in standards and 
technology be addressed. Furthermore, even with the technical capabilities in place, there 
are still many nontechnical issues for service-based CDS that will need to be overcome, 
such as legal uncertainties regarding medical liability and questions regarding the financial 
sustainability of a services-based approach to CDS delivery. While such issues are 
important and must be addressed to enable services-based CDS for WGS information, these 
issues are also of interest to, and being addressed by, the larger CDS community. For 
instance, the consistent and widespread adoption of a service-based CDS architecture may 
be greatly enhanced by related EHR certification criteria that are under consideration for 
Meaningful Use Stage 3, due out in 2017 [82]. Indeed, efforts are currently underway in 
the Health eDecisions initiative to develop and pilot standards that are being considered 
for this purpose [83]. Of note, however, regulations and EHR certification criteria related 
to Meaningful Use Stage 3 are still under development and are subject to change. 
Nevertheless, some major EHRs have already implemented, or have plans to implement, 
service-based CDS capabilities in the near future, irrespective of Meaningful Use 
requirements.   
 
Current efforts and future direction 
While this manuscript is largely theoretical, current efforts by the authors are 
underway to build and test a functional prototype of this system, with greater technical 
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details regarding specific specifications. Indeed, this prototype currently follows the 
methods described in this paper in an attempt to meet the requirements in the technical 
desiderata. Once demonstrated with a prototype, it would be appropriate to build out a more 
robust infrastructure and implement the architecture on a small scale within a clinical 
setting. Such an implementation could begin with single gene test results, and then move 
to more complex gene panels and whole genome sequences. Additionally, research and 
experience from these implementations may determine that performance issues and 
security may be less of a concern than previous thought. Moreover, as the architecture 
capabilities become available to more health care providers, it will become appropriate to 
develop genome-specific CDS knowledge.   
Also, as mentioned in the section on genome storage, future research will be needed 
to determine which genomic information will be essential for CDS knowledge. Indeed, a 
systematic review and analysis of potential CDS knowledge for genomic information could 
help determine the most important elements for genome-based CDS. Furthermore, the 
current architecture is primarily focused on (1) simple kinds of genomic variation (e.g., 
SNP variants within genes) and (2) variants with known clinical impact. However, current 
and future genomic discoveries may uncover complex interactions, which may require 
additional architectural considerations and modifications in order to support CDS. 
Likewise, by incorporating variant prediction algorithms such as VAAST, CDS could also 
become more involved with the interpretation of novel variants [45,46]. As a result, we do 
not presume the currently proposed architecture to be the final solution for WGS-based 
CDS. Rather, the current architecture provides a foundation for future development and 




The availability of a patient’s whole genome sequence has the potential to facilitate 
the practice of personalized health care in the clinic. While research efforts are producing 
significant discoveries in support of personalized medicine, many barriers exists which 
limit the effective utilization of these discoveries in a clinical setting. Such barriers include 
the complexity of genomic information, the changing nature of understanding of the 
genome, current result reporting methodologies, and limited availability of clinical 
genomics experts [9]. However, effectively designed CDS provided within the clinical 
workflow, offers a potential solution to support the effective clinical utilization of WGS 
information. Indeed, a well-coordinated, service-based CDS architecture represents a 
practical solution to provide WGS-enabled CDS at the point of care.    
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Figure 4.1: Desiderata for the integration of genomic data  
into EHRs described by Masys et al. 
 
Figure 4.2: Additional desiderata for the technical  
integration of WGS with CDS 
  
1. Maintain separation of primary molecular observations from the clinical 
interpretations of those data  
2. Support lossless data compression from primary molecular observations to 
clinically manageable subsets  
3. Maintain linkage of molecular observations to the laboratory methods used to 
generate them  
4. Support compact representation of clinically actionable subsets for optimal 
performance 
5. Simultaneously support human-viewable formats and machine-readable formats in 
order to facilitate implementation of decision support rules  
6. Anticipate fundamental changes in the understanding of human molecular variation  
7. Support both individual clinical care and discovery science 
8. CDS knowledge must have the potential to incorporate multiple genes and clinical 
information. 
9. Keep CDS knowledge separate from variant classification. 
10. CDS knowledge must have the capacity to support multiple EHR platforms with 
various data representations with minimal modification. 
11. Support a large number of gene variants while simplifying the CDS knowledge to 
the extent possible. 
12. Leverage current and developing CDS and genomics infrastructure and standards. 
13. Support a CDS knowledge base deployed at and developed by multiple 
independent organizations. 











Table 4.1:  A description of how the proposed architecture attempts 
 to satisfy each desiderata requirement in order 
 to overcome a WGS barrier to CDS
WGS barriers  Desiderata requirements  How the proposed architecture addresses requirements 
Clinical interpretations of genomic information can 
be dynamic [30]  
 
(Desiderata #1) Maintain separation of primary molecular 
observations from the clinical interpretations of those data 
The genome variant knowledge bases exists separately and 
independently from the genome databases 
WGS information contains a large amount of 
redundant and nonrelevant data [38] 
(Desiderata #2) Support lossless data compression from 
primary molecular observations to clinically manageable 
subsets  
Genome variant file formats are based on a reference 
sequence and a clinical genome database is used 
Genomic results may be different based upon 
laboratory methods [71]   
(Desiderata #3) Maintain linkage of molecular observations 
to the laboratory methods used to generate them  
Laboratory methods are included with the variant file in the full 
genome database 
A majority of a patient’s 3,000,000+ genome 
variants will not have a clinical impact [4] 
(Desiderata #4) Support compact representation of clinically 
actionable subsets for optimal performance 
Compact representation of clinically actionable informatics are 
available in the clinical genome database 
Computing on the genome will require data 
representations that are hard for humans to 
understand [61] 
(Desiderata #5) Simultaneously support human-viewable 
formats and machine-readable formats in order to facilitate 
implementation of decision support rules  
The machine-readable data format is used throughout the 
architecture, whereas a human viewable format is available 
through the genome interpreter 
Our understanding of the human genome is nascent 
and in the future may change significantly [72] 
(Desiderata #6) Anticipate fundamental changes in the 
understanding of human molecular variation 
The proposed SOA architecture design allows for the flexibility 
of components to adapt to additional requirements as needed 
Using available clinical and genomic information will 
be essential for research and discovery [73] 
 (Desiderata #7) Support both individual clinical care and 
discovery science 
The same methods used to gather clinical and genomic data for 
CDS can be used for research as well 
Relatively few diseases are caused by a single 
genetic variant alone [74] 
(Desiderata #8) CDS knowledge must have the potential to 
incorporate multiple genes and clinical information 
The CDS controller is able to collect all required clinical and 
genomic data required by the CDS knowledge base 
CDS knowledge may evolve independently of 
variant classifications [30] 
(Desiderata #9) Keep CDS knowledge separate from variant 
classification 
The CDS knowledge base is a separate component from the 
genome variant knowledge base 
Many organizations, with various EHR platforms, 
will likely not be able to develop their own CDS for 
WGS information [65] 
(Desiderata #10) CDS knowledge must have the capacity to 
support multiple EHR platforms with various data 
representations with minimal modification 
The architecture uses industry standards and approaches for 
scalable, interoperable CDS that are being considered for 
inclusion in EHR certification criteria related to Meaningful Use 
Stage 3 
A single gene can have 100s-1000s of variants with 
various clinical impacts [75] 
(Desiderata #11) Support a large number of gene variants 
while simplifying the CDS knowledge to the extent possible 
The information in the clinical genome database and required 
for CDS can simply consist of the gene and its clinical 
interpretation 
Re-inventing prior standards work on genomics and 
CDS just for this use case may prove to be futile [57] 
(Desiderata #12) Leverage current and developing CDS and 
genomics infrastructure and standards 
Health IT and genetics standards are used throughout the 
architecture where possible 
No single entity will be able to develop and maintain 
all possible CDS knowledge for WGS [69] 
(Desiderata #13) Support a CDS knowledge base deployed at 
and developed by multiple independent organizations 
Service-based CDS supports CDS knowledge developed and 
maintained by multiple independent organizations 
The file size and security concerns for WGS 
information are important [76] 
(Desiderata #14) Access and transmit only the genomic 
information necessary for CDS 
The CDS controller requests only the genome data needed for 










CLINICAL DECISION SUPPORT FOR WHOLE GENOME SEQUENCE 
INFORMATION LEVERAGING A SERVICE-ORIENTED 
 ARCHITECTURE: A PROTOTYPE3 
 
Introduction 
Having a patient’s whole genome sequence (WGS) information available to guide 
clinical decision-making has been an important goal of genome research, as WGS 
information could be used to improve clinical diagnosis, guide preventative efforts, and 
inform therapeutic decisions in the clinic [1]. Indeed, several clinical examples illustrate 
how WGS information has been used for the clinical diagnosis and treatment of patients 
with rare or previously undiagnosed diseases [2–4]. A patient’s WGS information available 
at the point of care can increase a clinician’s capacity to practice personalized medicine in 
a routine clinical care setting [5]. In fact, as a result of increasing availability of sequencing 
technology, as well as the exponentially declining costs of obtaining one’s genomic 
information, the application of WGS information to routine clinical care is becoming 
increasingly possible [6]. 
                                                          
3 This chapter has been submitted as a conference paper for the 2014 American Medical Informatics 
Association Annual Symposium. Co-authors include Salvador Rodriguez-Loya, Dr. Karen Eilbeck, and Dr. 






The need for clinical decision support for WGS 
Although WGS information has the potential to be a valuable resource for clinical 
decision-making, its effective application to routine clinical care will likely be hindered by 
a number of challenges. Examples of such challenges include (1) static laboratory reports 
intended for human consumption, (2) the complexity of genetic analysis, (3) limited 
physician proficiency in genetics, and (4) the lack of genetics professionals in the clinical 
workforce [7]. Nevertheless, these challenges could be overcome by means of clinical 
decision support (CDS). CDS entails providing clinicians, patients, and other healthcare 
stakeholders with pertinent knowledge and/or person-specific information, intelligently 
filtered or presented at appropriate times, to enhance health and health care [8]. CDS 
provided within the clinical workflow, and at the point and time of decision-making within 
the electronic health record (EHR), has been shown to be the most effective way to deliver 
CDS to clinicians [9]. To realize the potential of genome-guided clinical care, CDS, 
leveraging a patient’s WGS information, must be provided in real-time within the clinical 
workflow and the EHR [7].   
 
Desiderata for integrating genomic information 
 with the EHR and CDS 
To address the complexity and challenges of integrating genomic information with 
EHRs, Masys et al. developed a set of desired technical requirements for EHRs to support 
the integration of genomic information [10]. See Figure 5.1 for the list of these 
requirements. Welch et al. developed an additional set of requirements, extending the 






for WGS information [11]. See Figure 5.2 for a list of these requirements. Both of these 
efforts are aimed at providing guidance to system developers who are developing health IT 
capabilities for WGS information. 
 
Proposed CDS architecture for WGS information 
To satisfy the desiderata requirements described above, we previously proposed the 
use of a service-oriented architecture (SOA) to provide automatic CDS for WGS 
information at the point of care [12]. SOA is a software design approach which uses 
separate, independent software components known as services, which are self-contained 
components that have well-defined, understood capabilities [13]. SOA facilitates the 
reusability and standardization of processes, allowing for independent evolution and 
modifications to a particular service, reducing the burden of change on the overall system. 
Indeed, SOA offers many advantages to health information technology and CDS; as a 
result, its use is growing in health care [14]. Figure 5.4 shows a diagram of the SOA 
architecture proposed and described in further detail by Welch et al. [12]. A brief summary 
of each component is provided here: 
 Genome sequencing and annotation- This component of the architecture is 
responsible for making the patient’s genome information available and 
providing the genome with relevant annotations (e.g., location of variants 
relative to genes, impact of variants on genes, etc.). The annotation process 
leverages variant knowledge contained in the genome variant knowledge base.  
 Genome variant knowledge base- This is a knowledge repository of known 






responsibility of these knowledge repositories is to maintain the most up-to-
date and accurate variant interpretations, which is important as variant 
interpretations are known to change over time [15].  
 Genome database- In the proposed architecture, a patient’s genome is stored 
in a genome database, separate from clinical information (e.g., EHR). This 
database securely stores patients’ genomes along with the most up-to-date 
variant interpretations from the genome variant knowledge base. This database 
also provides a standardized interface for access to a patient’s genomic 
information.   
 CDS knowledge base- The role of the CDS knowledge base is to process the 
patient-specific clinical and genomic information provided to it. It 
subsequently returns patient-specific, knowledge-based recommendations 
and/or information to support clinical care.  
 Electronic health record- The EHR provides the patient’s clinical information 
used by the CDS knowledge base. The EHR is also responsible for actions 
which trigger CDS requests and the presentation of CDS results within the 
clinical workflow. 
 CDS controller- The CDS controller is responsible for processing a CDS 
request and assuring that all required data for CDS knowledge are available. If 
additional patient data are needed for CDS, the CDS controller makes a request 
to other data repositories (e.g., genome database) for the required information.  
This manuscript describes our effort to build a functional prototype of the 






describe the open-source components and health IT standards used to develop this 
prototype. Furthermore, we describe the methods used to evaluate the prototype using a 
clinical use case involving a patient at increased risk for Lynch syndrome. Finally, we have 
identified areas that will require additional research and development in the future. While 
others have built CDS capabilities for genomics [16–18], to our knowledge this work is the 
first to describe a system that adheres to the technical desiderata [10,11] and uses a SOA 
approach to provide WGS-guided CDS within the clinical workflow within the EHR. 
 
Materials and Methods 
Components used and configuration 
Genome data acquisition and database storage 
We used the 10Gen data set, which represents the first ten publicly available human 
genomes in a standardized genome variation format (GVF), for the genomic information 
used in this study [19].  These genomes represent three different ethnicities (African, Asian, 
and Caucasian) and several sequencing platforms including SOLiD, Illumina, Sanger, 
Roche 454, CGenomics, and Helicos [20]. The genomes were annotated using the Web-
based Omicia Opal genome annotation platform.   
 
Genome database 
To store a patient’s genomic information and make it available for CDS data 
requests, we implemented a relational database using MySQL Community Server (version 
5.6.15) and the HeidiSQL open-source database manager [21]. In this database, we created 






quotes): (1) ‘MRN’ which is the patient’s unique medical record number (MRN) that 
matches the patient’s MRN in the Tolven open-source EHR; (2) ‘gene’ is the gene where 
the variant resides, represented using HUGO (Human Genome Organization) Gene 
Nomenclature Committee (HGNC) standardized nomenclature; (3) ‘refSNP’ is the 
reference SNP ID number; (4)‘nuc_var’ is the nucleotide variant represented in Human 
Genome Variation Society (HGVS) nomenclature; (5) ‘pro_var’ is the protein variant also 
represented in HGVS nomenclature; (6) ‘interpretation’ is the clinical impact of the variant 
provided by the ClinVar genome variant knowledge base; and (7) ‘id’ is an auto-
incremented value for the primary key of the table. The 10Gen genomes were exported 
from Omicia as CSV files and then imported into the database through a database import 
process available through HeidiSQL. Code to regenerate the tables and import the genomes 
is available in Appendix D.  
To support external access to a patient’s genomic data stored in the database, we 
developed a Web service interface deployed as a Java application within the JBoss 
Enterprise Application Platform version 6.1. This Web service interface provides access to 
the database content using the HL7 Retrieve, Locate, and Update Service (RLUS) standard 
[22]. The RLUS specification can be adapted to different semantic content formats. For the 
present prototype, we used the HL7 Virtual Medical Record (vMR) as the semantic content 
format within the RLUS-based Web service. See http://tinyurl.com/n3zksjd for the location 
of the RLUS specification used in this prototype. The location of the code used for the Web 
service interface can be found at https://bitbucket.org/Salvador_Rdz/genome-data-app-







ClinVar genome variant knowledge base 
We used ClinVar as the genome variant knowledge base in this prototype. ClinVar 
is a publicly available repository of human genome sequence variations and associated 
phenotypes supported by the National Center for Biotechnology Information of the U.S. 
National Library of Medicine [23]. ClinVar currently does not support service calls to its 
knowledge base, so we replicated this functionality by developing a second table in the 
genome database called ‘genomekb’ and imported a subset of ClinVar data into this table. 
A ClinVar full data release was downloaded directly from the ClinVar FTP site to a Linux 
server and transformed into a format suitable for database import using XSLT [24]. See 
Appendix D for the code used to download and transform the ClinVar file. We created a 
SQL statement to update the interpretation field in the ‘patient_genome’ table from the 
interpretation field in the ‘genomekb’ table, based upon matches in the gene and variant 
between the two tables. This SQL code is also available in Appendix D. 
 
Tolven electronic health record 
To store the patient’s clinical information and provide a clinical workflow interface 
for CDS, we used the open-source Tolven electronic Clinician Health Record (eCHR™), 
which is provided as part of the Tolven platform [25]. Tolven eCHR™ is an Office of the 
National Coordinator (ONC) certified clinical information system which supports basic 
clinical processes and information exchange. The Tolven platform supports several 
additional components including ePrescribing, scheduling, and analytics. Tolven was 
selected because of (1) its open-source code; (2) its ability to be configured and 






and (4) its use of several terminology standards such as Current Procedural Terminology 
(CPT), Logical Observation Identifiers Names and Codes (LOINC), and RxNorm. 
Furthermore, third-party plugins can be developed to extend the functionality of the Tolven 
platform. We developed a plugin for Tolven using Java Enterprise Edition (version 1.6). 
The plugin is designed to serve three important purposes for the prototype: (1) to access 
the patient’s clinical data stored in Tolven; (2) to create a vMR document containing the 
patient’s data; and (3) to communicate with an external CDS Web service using the HL7 
(Decision Support Service) DSS standard.   
 
SwitchYard CDS controller  
The CDS controller plays a central coordinating role in this architecture. It first 
processes a CDS request from Tolven and checks that all required data for CDS inferencing 
are available. It identifies that the genomic data are not available so it makes a data request 
to the genome database for additional information. We used the open source solution 
SwitchYard (JBoss) to provide these functions. SwitchYard is a component-based SOA 
development framework which combines several useful components and functions for 
SOA into one application, including Apache Camel, Java Enterprise Edition, business 
process management (BPM), orchestration, routing, validation, and transformation. Within 
SwitchYard, we developed a composite service that includes five components: 
CamelServiceRoute, ProcessComponent, VerifyGenomeData, RequestGenomeData and 
IntegrateGenomeData.  Figure 5.5 represents the workflow of the VerifyGenomeData 
component which checks for genome data in the vMR and, if it is not available, makes a 






service adaptors for SwitchYard to request and receive data from other components of the 
CDS architecture. These include (1) an adaptor for the HL7 RLUS standard to interface 
with the genome database Web service and (2) an adaptor for the HL7 DSS standard to 
interface with the Tolven EHR and OpenCDS.  
 
OpenCDS 
For the final component of the architecture, we used OpenCDS 
(http://www.OpenCDS.org) to serve as the CDS knowledge base. OpenCDS is an open-
source, Java-based CDS framework designed to enable the delivery of CDS as a Web 
service compliant with the HL7 DSS standard. OpenCDS provides a knowledge authoring 
environment and CDS rules engine. Internally, OpenCDS uses the vMR as its data model 
and JBoss Drools as its inferencing engine. OpenCDS also manages and uses its own 
terminology within the Apelon Distributed Terminology System (DTS), with mappings 
created to standard terminologies such as the Systematized Nomenclature of Medicine — 
Clinical Terms (SNOMED CT) and LOINC. For this prototype, we deployed a new 
instance of OpenCDS and created the CDS rule logic in the Web-based knowledge 
authoring environment for Drools known as Guvnor. Figure 5.6 shows a CDS business rule 
authored in Guvnor and used in this prototype. After the CDS rule was created and tested 
in Guvnor, it was deployed within the OpenCDS run-time environment. Several vocabulary 
terms required by the rules were added to the OpenCDS terminology in the Apelon DTS 
instance used by OpenCDS. The vocabulary terms and location of the knowledge 








HL7 Decision Support Service standard 
The DSS standard specifies a standard interface for providing CDS as a service [26] 
and is adopted by both HL7 and the Object Management Group (OMG) standards 
development organizations. The DSS standard includes three major interfaces including 
(1) evaluation, used to evaluate patient data and generate patient-specific results; (2) 
metadata discovery, to identify metadata and knowledge modules of a service; and (3) 
query, which is used to query for knowledge modules of interest. For this prototype, we 
used the evaluateAtSpecifiedTime request interface, which includes a payload section in 
which a base64 encoded version of the vMR is placed. 
 
HL7 Virtual Medical Record Standard 
The Virtual Medical Record (vMR) is a standard HL7 clinical data model designed 
for CDS [27]. The vMR data model can represent patient-specific classes such as 
demographics, encounters, procedures, problems, medications, laboratory results, and 
observations. A patient’s clinical data are modeled using these various vMR classes and 
elements. To represent the patient’s genome information, we used the ObservationResult 
class. Specifically, observationFocus was used to represent the gene name in HGNC 
format, observationValue was used to represent the nucleotide variant in HGVS format, 
and interpretation was used to represent the variant clinical interpretation in LOINC. See 
Figure 5.7 for an example genome variant result in vMR format. The most recent HL7-
approved version of the vMR is Release 2. However, for this prototype we used Release 1 






HL7 Retrieve, Locate, and Update Service 
The HL7 Retrieve, Locate, and Update Service (RLUS) defines the service 
interface to locate, retrieve, and update resources among and within healthcare 
organizations [22]. This specification was designed to support SOA in healthcare. The HL7 
RLUS specification defines several methods including describe, discard, get, initialize, 
list, locate, and put. In our prototype, we used RLUS to request a patient’s genomic 
information from the genome database using the describe and get methods. Describe 
returns a detailed schema definition and get retrieves patient data based on parameters 
supplied in the RLUS retrieval request.     
 
Gene and variant nomenclature 
Several genome standards were used to represent genomic information in this 
prototype. To represent genes, we used names approved by HGNC [28]. We used three 
types of standardized genome variant representations in the prototype: (1) the refSNP 
number assigned to a sequence variant by dbSNP [29]; (2) the nucleotide variant in HGVS 
nomenclature format for coding sequence [30]; and (3) the protein variant in HGVS 
nomenclature for protein variation. Finally, we used LOINC to represent the possible 
interpretations of gene variants, which include pathogenic, presumed pathogenic, unknown 
significance, benign, and presumed benign [31]. 
 
The CDS process 
The previous sections describe the components used in the prototype and their 






CDS using WGS information within the EHR. With all components of the prototype in 
place and functioning properly, the sequential steps of the application are as follows: 
1. A patient’s clinical data are recorded in Tolven by the clinician. When the 
patient’s chart is modified and saved, a CDS request is triggered by the 
OpenCDS plugin in Tolven. The plugin proceeds to gather the patient’s 
clinical data from Tolven and transform the data into the vMR format. When 
the patient’s clinical data are all in vMR format, they are base64-encoded, 
placed into the DSS payload, and sent to the SwitchYard CDS controller.  
2. When SwitchYard receives the DSS request with clinical data in vMR 
format, it validates the data against a vMR schema template defining the 
required data for the requested CDS knowledge module. In this case, 
SwitchYard identifies that the genomic data required by the CDS module 
are missing. It then creates a RLUS request to obtain that required 
information from the genome database.  
3. The genome database Web service interface receives the RLUS request 
from SwitchYard. This interface retrieves the requested information from 
the genome database, which includes the gene and clinical interpretation 
(the return of specific variants are also available upon request). The 
interface creates a response RLUS message and inserts a vMR payload of 
the genomic information. 
4. SwitchYard receives the RLUS response from the genome Web service 
interface and merges the genome vMR with the clinical data vMR from 






merged vMR is sent to OpenCDS. 
5.  OpenCDS receives the DSS request and processes the data contained in the 
vMR against rules in the requested knowledge module (MLH1). A CDS 
result is produced and sent back to SwitchYard in a DSS response.  
6. SwitchYard receives the response from OpenCDS and forwards the 
message to Tolven. 
7. When the Tolven plugin receives the response, it renders the response as an 
alert within the Tolven user interface such that the CDS is provided within 
the clinical workflow and at the time of decision-making, 
  
Clinical use case and evaluation methods 
To assess whether the prototype is functional we implemented the following 
clinical scenario and evaluated the performance of the prototype. 
 
Clinical use case: Lynch syndrome risk assessment 
Lynch syndrome (or hereditary nonpolyposis colorectal cancer) is an autosomal 
dominant genetic condition caused by pathogenic mutations in mismatch repair genes, such 
as MSH2, MLH1, MSH6, and PMS2 [32]. These mutations impact the ability of a cell to 
repair DNA replication errors that occur during cell division. As the cell continues to 
divide, these mutations continue to accumulate throughout the genome. These mutations 
may ultimately lead to uncontrolled cell proliferation and thus cancer. Patients who have a 
pathogenic variant in any of these genes possess the greatest risk for colorectal cancer, and 






other body sites. Every year in the U.S., approximately 4,000-7,000 new cases of colorectal 
cancer are caused by Lynch syndrome [32]. It is recommended that patients at increased 
risk for Lynch syndrome should receive a colonoscopy every one to two years starting 
around the age of 20 years [33]. While family history is a strong indicator for risk, genetic 
testing is the definitive test for a patient’s Lynch syndrome risk. Genetic screening for the 
disease, although currently expensive, will likely become easier when WGS information is 
clinically available for routine care [34]. Even then, some clinicians may not be familiar 
with Lynch syndrome nor the best practices for risk mitigation and management. CDS can 
play an important role in the awareness and management of Lynch syndrome. 
 
Implementation of the clinical use case 
To assess the ability of this prototype architecture to provide point-of-care CDS for 
Lynch syndrome, we created and implemented the example clinical scenario found in 
Figure 5.3. To implement this clinical scenario in the prototype, we created a new 33 year 
old patient in Tolven. For simplicity and demonstration purposes, we tested the architecture 
using a single gene (MLH1) with a pathogenic variant. We assigned the publicly available 
Venter genome to the test patient, which did not have a pathogenic mutation in the MLH1 
gene [35]. Therefore, we created a known pathogenic MLH1 mutation using a SQL script 
described in Appendix D. This genome change was created previous to a genome 
knowledge base update of the ‘interpretation’ database field in the patient_genome table. 
A CDS business rule representing the MLH1 recommendation for colonoscopy was created 
in Guvnor and deployed on the OpenCDS run time environment (see Figure 5.6). The CDS 







To test the performance of the architecture we used the free, open-source load 
testing software LoadUI (www.loadui.org) running on a Windows 7 (64-bit) machine with 
two processors and four gigabytes of RAM. In order to identify sources of latency, we 
tested each service component of the architecture separately, which included the genome 
application service running on a Linux Ubuntu 12.04 (64-bit) server with eight processors 
and 16 gigabytes of RAM, as well as the OpenCDS service running on a Linux CentOS 
v5.8 (64-bit) with four processors and four gigabytes of RAM. We also tested the 
performance of the SwitchYard CDS Controller (also running on the Linux Ubuntu server 
previously described) which included service calls to both the genome application and 
OpenCDS within its evaluation. As such, the evaluation of the CDS controller most closely 
represents the overall performance of the architecture. Each component was tested with a 
random load balance of 100 simultaneous users every 10 seconds using the same data 
requirements described in the clinical scenario. The overall performance evaluation was 
limited to 20 simultaneous users as a result of performance issues related to running 
Switchyard on a machine with limited processor capabilities.  
 
Results 
The objective of this study was to develop a functional prototype of our proposed 
architecture [12]. To that end, we implemented a prototype and verified that a patient with 
a clinical scenario described in Figure 5.3 was evaluated properly by the prototype. Figure 
5.8 shows a screenshot of the CDS recommendation successfully generated through the 







The genome application (which includes the service interface and database request) 
handled 3,109 requests over a five minute period. This genome application’s fastest request 
took 25 milliseconds (ms), and the slowest took 697 ms, with an average of 40 ms (SD 
47.44 ms). OpenCDS handled 3,015 requests over a five minute period. The fastest request 
took 7 ms, and the slowest took 914 ms, with an average of 12 ms (SD 17.04 ms). We also 
evaluated the performance of the CDS controller, which includes service calls to the 
genome application and OpenCDS and thus closely represents the overall performance of 
the architecture. Due to hardware limitations of our machine, we limited the testing to 20 
simultaneous users. The CDS controller handled 650 requests over a five minute period. 
The fastest request took 356 ms, the slowest took 4,243 ms, with an average of 944 ms (SD 
621.04). It is important to note that the average response time was under one second. See 
Table 5.1 for a performance summary. 
 
Discussion 
As demonstrated by this prototype and demonstration, a service-oriented CDS 
architecture is able to support the provision of genome-guided CDS at the point of care 
within the EHR. Indeed, this prototype leverages many standards and open-source 











Throughout the process of developing the prototype of this architecture, several 
issues were identified. We used ClinVar as the genome variant knowledge base for this 
prototype because it was easily accessible and publicly available. Unfortunately, ClinVar 
is still in a very early stage with regards to its variant knowledge base, limiting its ability 
to provide clinical interpretations for relevant variants. Specifically, the available variant 
knowledge in ClinVar is a small, but growing, subset of all available variant knowledge 
[36,37]. Nevertheless, it is expected that ClinVar will improve over time as more 
laboratories begin contributing their variant knowledge. Also, variants reported to ClinVar 
can range in quality on a scale from one to five stars, ranging from a single submitter’s 
interpretation to variants reviewed and submitted by expert panels. This variable quality of 
variant interpretation or potential disagreement between submitters can be challenging for 
CDS to manage. Ideally, variant interpretations used in CDS should meet a minimum 
threshold of quality and confidence. A recent NIH-funded initiative called ClinGen is 
expected to improve the data available in ClinVar [38]. Although other genome variant 
knowledge bases are also available (such as the Human Genome Mutation Database), we 
did not integrate them with this prototype due to the time and cost associated with each 
integration. Integrating such variant knowledge bases into the architecture is an anticipated 
future effort. Nevertheless, once ClinVar becomes more developed, we believe it 
represents an ideal resource for genome variant knowledge management because of its 
public financing and its potential to become the largest single repository of genome variant 
knowledge [12]. Finally, many of the variant locations were based upon differing reference 






genome. Ideally, all variants used architecture should be updated to a single reference 
genome [39].   
Another important issue we identified in this work is the speed and response time 
of the CDS architecture. The first of Bates et al. 10 Commandments for effective CDS is 
that ‘Speed is everything,’ in that CDS response time should be less than a second [40]. 
Unfortunately with SOA architecture, because several disparate components are involved 
to provide CDS, speed and performance can be a major challenge. This is indeed the case 
with our prototype. With heavy loads (>30 simultaneous users), we observed response 
times to increase dramatically to be several seconds. Moreover, as CDS knowledge and 
data requirements become more complex, this response time will likely increase. Although 
our results show that around 20-30 simultaneous requests is the most the prototype could 
process before it became unreasonable for CDS, many computer science techniques such 
as increasing processing power, parallel processing, and load balancing can be used to 
improve performance of the overall CDS processes. Nevertheless, the goal of this study 
was to show that the architectural approach could work. We believe this work has 
accomplished this goal, however, we still believe there is much testing and optimization 
that can be done to improve the performance and response time of the architecture. 
 
Strengths and limitations 
An important strength of this work is the use of freely available, open-source 
components. Indeed, anyone with sufficient training in the technologies used could rebuild 
this architecture without needing to purchase and use proprietary software or components. 






possible. Such standards and terminologies include the HL7 DSS standard, HL7 vMR 
standard, LOINC, HGNC, and HGVS. As a result, we were able to demonstrate that 
standards-based approaches are feasible for increasing the likelihood of interoperability 
with other health IT systems in the future. 
A limitation of the study is that we only demonstrated this architecture working 
using a simple scenario in one clinical use case (Lynch syndrome risk assessment). While, 
there are many other clinical and genomic scenarios (such as pharmacogenomics) that 
could be tested and demonstrated with this architecture, the scope of this effort was limited 
to assessing whether the proposed prototype could deliver standards-based CDS within the 
clinical workflow and within the EHR. Nevertheless, we are planning to demonstrate the 
extensibility of the architecture with various clinical genomic use cases in future work. 
Another limitation of the study is that we have only integrated the CDS architecture with a 
single EHR. While the primary aim of the current effort was to demonstrate minimum 
feasibility, future efforts will need to focus on integrating the architecture with other EHRs. 
Of note, the integration of SOA CDS capabilities into various EHRs is part of larger 




While we were able to demonstrate the feasibility of this architecture using open-
source solutions and standards, it took a significant amount of configuration of these 
components to make this possible. As a result, a future direction of this research is to 






to set up and run with minimal modification. Such a solution could potentially consist of a 
virtual machine image which includes a preconfigured genome database already linked to 
several genome variant knowledge bases, OpenCDS configured for genome rule authoring, 
and SwitchYard set up to support WGS-enabled CDS. Furthermore, it will be important to 
develop and include integration plugins for commercial EHR systems. Indeed, EHR 
systems are starting to support service capabilities and future Meaningful Use guidelines 
may require all EHRs to support them, meaning this architecture has the potential to be 
used on a widespread basis for WGS CDS in the near future [41]. Likewise, as the 
standards-based CDS integration with EHRs become more widespread, it will be important 
to test the functionality with end-users and conduct clinical trials evaluating the clinical 
impact of genome-guided CDS using this approach.  
Another important future effort is to build the genomic CDS knowledge base and 
expand the current genome database. As this architecture supports a CDS knowledge base 
that can serve multiple health care organizations, it may be possible to develop a genomic 
CDS knowledge base which could be shared among these organizations. Such an effort 
could involve the collaboration of informaticists, geneticists, and clinical experts to 
implement published clinical genomics guidelines into a computable CDS knowledge 
representation. Furthermore, such experts could also review the literature and current 
clinical practices to develop new genomic CDS knowledge for clinical care. During this 
processes of developing a genomic CDS knowledge base, additional data requirements for 
inclusion in the genome database will likely be identified. For example, in the current 
version of the genome database, only genes and variants are included. While these data 






would not be sufficient for autosomal recessive genetic conditions and other types of 
genomic use cases (e.g., SNP-based testing). As a result, it will be necessary to add 
additional genomic information for CDS, such as chromosome number, zygosity, tandem 
repeat number, or sequencing quality scores. These additional genomic data requirements 
could potentially be identified though a systematic review of the literature and the 
involvement of various domain experts.      
 
Conclusion 
Using WGS information in the clinic for routine clinical care may be challenging 
for clinicians to manage without assistance. CDS provided within the clinical workflow, at 
the time of decision-making, provides a feasible solution to enable genetically-guided 
personalized medicine. To evaluate this potential solution, we developed and tested a 
functional CDS architecture for WGS information using SOA design principles. Through 
this effort, we were able to demonstrate that a functional prototype of this approach is 
capable of providing genome-guided CDS within the clinical workflow, and within the 
EHR. While future research and development is necessary before such an approach can be 
used in a clinical setting, this study demonstrates that the approach is feasible and valid. 
We therefore speculate that this work will help guide future research and development on 
the use of WGS-based CDS to support personalized healthcare.                
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Figure 5.1: Desiderata for the integration of genomic data into  
EHRs described by Masys et al. 
 
Figure 5.2: Additional desiderata for the technical integration  
of WGS with CDS described by Welch et al. 
 




1. Maintain separation of primary molecular observations from the clinical interpretations 
of those data  
2. Support lossless data compression from primary molecular observations to clinically 
manageable subsets  
3. Maintain linkage of molecular observations to the laboratory methods used to generate 
them  
4. Support compact representation of clinically actionable subsets for optimal 
performance 
5. Simultaneously support human-viewable formats and machine-readable formats in 
order to facilitate implementation of decision support rules  
6. Anticipate fundamental changes in the understanding of human molecular variation  
7. Support both individual clinical care and discovery science 
8. CDS knowledge must have the potential to incorporate multiple genes and clinical 
information. 
9. Keep CDS knowledge separate from variant classification. 
10. CDS knowledge must have the capacity to support multiple EHR platforms with 
various data representations with minimal modification. 
11. Support a large number of gene variants while simplifying the CDS knowledge to the 
extent possible. 
12. Leverage current and developing CDS and genomics infrastructure and standards. 
13. Support a CDS knowledge base deployed at and developed by multiple independent 
organizations. 
14. Access and transmit only the genomic information necessary for CDS. 
The patient is a 32 years old male, with no personal history of colon cancer and no prior 
colonoscopies. The patient does not know his family health history. This patient previously had 
his genome sequenced, and this WGS information is available for assessment by CDS. This 
patient has a pathogenic mutation in the MLH1 gene, a gene associated with a high risk for 
Lynch syndrome. The clinical recommendation established by his healthcare organization is to 
recommend that patients over 20 years old with pathogenic mutations in the MLH1 gene receive 







Figure 5.4: Overview of proposed CDS architecture for WGS 




Figure 5.5: A visual diagram of the BPMN used within 











Figure 5.6: A screenshot of the MLH1 business rule 
 developed in OpenCDS 
 
 
Figure 5.7: A vMR representation of a pathogenic  
MLH1 genome variant 
 
 
Figure 5.8: A screenshot of the Tolven EHR with the CDS  






Table 5.1: Performance results of the architecture  







time (time in 
ms) 
Max request 









100 3109 25 697 40 47.77 
OpenCDS 100 3015 7 914 12 17.04 












The previous chapters of this dissertation outline a body of work that represents an 
advance in the field of biomedical informatics in the domain of clinical decision support 
(CDS) for whole genome sequence (WGS) information. Chapter 1 represented a systematic 
review of the literature in the CDS for genetically-guided personalized medicine domain 
which identified a gap in published research in the area of CDS for WGS information. 
Chapter 2 described the need and justification for researching and developing CDS 
capabilities for WGS information. Chapter 3 built on previous work by Masys et al. entitled 
“Technical desiderata for the integration of genomic data into Electronic Health Records” 
by extending the desiderata with additional requirements specifically for CDS. Chapter 4 
laid out the description and justifications for a proposed CDS architecture capable of 
supporting WGS information while adhering to the desiderata requirements. Finally, 
Chapter 5 described the efforts to build and test a functional prototype of this architecture.     
Given the early stage of research on CDS for WGS, and the pending demand for such 
solutions in health care, this body of work has the potential to shape future research and 
development in this domain. Indeed, the work completed in this effort provides a 
framework and demonstration of feasibility which future research and development can 
build upon and improve. It is not the intention of this work to stand alone in its capabilities; 






Certainly, it will require the cooperation and interdependence of several independent 
entities and organizations to realize the full potential of the approaches described in this 
work. To that end, we look forward to future research by ourselves and others to fully 
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CDS controller: A component of a SOA architecture which links several services 
together.  
CDS knowledge: A representation of clinical knowledge in the form of logic, rules, 
expressions, guidelines or algorithms. 
CDS knowledge base: A repository of CDS knowledge. 
Clinical genome database: A repository which stores only variants of known or 
potential clinical importance. 
Clinical interpretation: The clinical impact of a variant. 
Full genome database: A repository which stores all variants of an individual’s genome. 
Genome annotation: The process of locating and identifying key features of a genome. 
Genome interpreter: A visual interface which allows a clinician to manually review a 
patient’s genome variants. 
Genome sequencing: The process of obtaining the DNA sequence of an individual. 
Genome variant knowledge base: A repository of variants and associated clinical 
interpretation. 
Genome variant: A difference in a genome relative to a reference genome sequence. 
Service: A self-contained component with well-defined, understood capabilities. 
Service oriented architecture (SOA): A software design methodology which contains 











COMPUTER CODE AND CONFIGURATION USED TO  









SQL code to recreate database tables 
CREATE DATABASE 'genomedb' 
  
CREATE TABLE `patient_genome` ( 
`MRN` INT(10) NULL DEFAULT NULL, 
`gene` VARCHAR(50) NULL DEFAULT NULL, 
`refseq` VARCHAR(50) NULL DEFAULT NULL, 
`nuc_var` VARCHAR(100) NULL DEFAULT NULL, 
`pro_var` VARCHAR(100) NULL DEFAULT NULL, 
`interpretation` VARCHAR(100) NULL DEFAULT NULL, 
`id` INT(10) NOT NULL AUTO_INCREMENT, 
PRIMARY KEY (`id`) 
) 
COMMENT='stores patient-specific genetic information will be queried by 
the web service' 
ENGINE=InnoDB; 
 
CREATE TABLE `gene_variant_table` ( 
`ClinVarSetID` INT(11) NOT NULL, 
`interpretation` VARCHAR(45) NULL DEFAULT NULL, 
`nucleotide_variant` VARCHAR(90) NULL DEFAULT NULL, 
`gene_name` VARCHAR(30) NULL DEFAULT NULL, 
PRIMARY KEY (`ClinVarSetID`) 
) 
COMMENT='stores gene variants from ClinVar, used to update 
interpretations in patient_genome table' 
 
 
Download ClinVar XML data 
$ wget ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/xml/ClinVarFullRelease_2014-01.xml.gz 










XSLT code to transform ClinVar XML to database import XML 






 <xsl:for-each select="ReleaseSet/ClinVarSet"> 
  <xsl:for-each 
select="ReferenceClinVarAssertion/MeasureSet/Measure/AttributeSet/Attrib
ute[@Type='HGVS, coding, RefSeq' or @Type='HGVS, protein'] | 
eferenceClinVarAssertion/MeasureSet/Measure/AttributeSet/XRef[@DB='dbSNP
']">    
  <row> 
   <field name='ClinVarSetID'><xsl:value-of 
select="../../../../../@ID"/></field>  
   <field name='interpretation'><xsl:value-of 
select="../../../../ClinicalSignificance/Description"/> </field> 
   <xsl:if test="@Type='HGVS, coding, RefSeq' or 
@Type='HGVS, protein'"> 
    <field name='{@Type}'><xsl:value-of 
select="."/></field> 
   </xsl:if> 
   <xsl:if test="@DB='dbSNP'"> 
    <field name='dbSNP'>rs<xsl:value-of 
select="@ID"/></field> 
   </xsl:if>  
   <field name='gene_name'><xsl:value-of 
select="../../../Measure/MeasureRelationship/Symbol/ElementValue"/></fie
ld> 
  </row> 
  <xsl:text>&#xa;</xsl:text> 
   </xsl:for-each>  
  </xsl:for-each> 
  </list> 
 </xsl:template> 
</xsl:stylesheet>   
 
 
Program used to run XSLT on ClinVar XML file 




SQL import CSV to database code 
LOAD XML LOCAL INFILE 
'C:\\Users\\bmw\\SkyDrive\\Documents\\PhD\\Thesis\\Project\\ClinVar\\Cli






Update Variant Interpretation from GenomeKB Table 
UPDATE IGNORE patient_genome 
SET interpretation =(SELECT genomekb.interpretation FROM genomekb 
WHERE patient_genome.gene = genomekb.gene 
AND (patient_genome.refSNP = genomekb.refSNP 
OR  patient_genome.nuc_var = genomekb.nuc_var; 
 
Location of the CDS knowledge developed in OpenCDS 
http://tolven.chpc.utah.edu:8081/drools-guvnor/org.drools.guvnor.Guvnor/Guvnor.jsp 
 
LOINC terms added to the Apelon DTS instance 
 
 
Code used to create the MLH1 mutation in the test patient’s genome 
insert into patient_genome 
values ('33333', 'MLH1', null, ’NM_000249.3:c.982C>T’, 
‘NP_000240.1:p.Gln328Ter’, null, default); 
 
 
 
 
